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ABSTRACT 
Background: Allergic disorders, including eczema, asthma, and rhinitis, have emerged 
as a global public health concern due to their elevated prevalence and the associated 
clinical morbidity. Environmental, immunologic, and genetic factors have been 
implicated in the pathogenesis of allergic disorders. Allergic sensitization (representing 
deviated immune responses) and filaggrin gene (FLG) variants (leading to dysfunctional 
epidermal barrier) have shown to be common predisposing factors in the development of 
allergic disorders. However, there is a lack of knowledge on their joint effects on the 
development of single and multiple (coexistence) allergic disorders. More recently, 
epigenetic mechanisms, such as DNA methylation, have emerged as potentially important 
factors in the development of such complex diseases; however, the extent to which DNA 
methylation associates with allergic disorders is unclear. 
Objectives: This dissertation sought to (i) determine whether eczema and/or allergic 
sensitization is an effect modifier of the association between ‘FLG variants and asthma’ 
and ‘FLG variants and rhinitis’, (ii) test whether FLG variants and allergic sensitization 
jointly predispose to the comorbidity of eczema, asthma and rhinitis, and (iii) examine 
associations between DNA methylation across the epidermal differentiation complex 
(EDC) genomic region with eczema status. 
Methods: The Isle of Wight (IOW) birth cohort, a population-based sample of 1,456 
infants born between January 1989 and February 1990, was prospectively assessed at 
ages 1, 2, 4, 10, and 18 years. Repeated measurements of eczema, asthma, rhinitis, and 
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allergic sensitization (documented by skin prick tests) were available for all follow-ups. 
FLG variants R501X, 2282del4, and S3247X were genotyped in 1,150 participants. Log-
binomial regression models were applied to test for associations and statistical 
interactions on multiplicative scale. On the other hand, DNA methylation was measured 
in a subsample (n = 367) of the IOW participants at age 18 years (discovery cohort) and 
in two semi-independent samples (replication cohorts I and II). Associations between 
eczema status and DNA methylation were assessed using linear regression. 
Results: FLG variants were associated with increased risk of asthma and rhinitis. Both 
eczema status (RRinteraction = 1.96, Pinteraction = 0.006) and allergic sensitization (RRinteraction 
= 1.58, Pinteraction = 0.013) modified the association between FLG variants and asthma, but 
not the association with rhinitis. The combined effect of both risk factors increased the 
risk of coexisting “eczema and asthma” (RR = 13.67, 95% CI: 7.35 – 25.42), “asthma and 
rhinitis” (RR = 7.46, 95% CI: 5.07 – 10.98), and “eczema, asthma, and rhinitis” (RR = 
23.44, 95% CI: 12.27 – 44.78). On the other hand, Differential DNA methylation of CpG 
site cg12048339 (located within promoter of S100A6 gene) was associated with eczema 
specifically among female participants of all study cohorts; whereas, aberrant DNA 
methylation of cg10959711 (located within promoter of S100A11 gene) associated with 
eczema among male participants in all study samples. 
Conclusions: Allergic sensitization and eczema modulated the association between FLG 
variants and asthma, but not rhinitis; implying that the mechanisms and pathways through 
which FLG variants predispose to increased risk of asthma and rhinitis may be different. 
Moreover, the coexistence of allergic disorders is frequent and allergic sensitization and 
FLG variants jointly increased risk of allergic comorbidities, which may represent more 
vii 
severe and complex clinical phenotypes. Results of an exploratory investigation 
demonstrated that DNA methylation of the EDC locus could be an important factor in the 
development of eczema in a sex-specific manner. Future studies corroborating our 
findings are needed. 
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CHAPTER 1 
INTRODUCTION 
1.1 BACKGROUND 
Allergic disorders, including eczema, asthma, and rhinitis, have emerged as a 
global public health concern [1]. The clinical morbidity associated with allergic disorders 
that leads to social and economic burden on families and societies further classify these 
disorders as major global public-health challenges [1, 2]. The direct annual cost 
associated with clinical management of eczema alone was estimated to be £47 ($76) 
million in the United Kingdom, with families bearing £17 ($27) million of disease costs 
[3]. Furthermore, Asthma has even greater economic burden, costing £843 million 
($1.368 billion) annually [3]. The elevated economic burden and clinical morbidity 
associated with such chronic diseases, clearly demonstrates the need for developing cost-
effective intervention and prevention strategies that aim at reducing the burden associated 
with allergic disorders. However, to reach the aforementioned goal, there is a need to 
better understand the natural history and the biological mechanisms that underlie the 
clinical manifestation of these complex disorders at different developmental stages. 
The International Study of Asthma and Allergies in Childhood (ISAAC) provides 
unmatched opportunity to explore the trends in prevalence of allergic disorders over time 
[4]. Reports based on the ISAAC study revealed the existence of global variations in the 
prevalence of allergic disorders [5-8]. During the last 3 decades, industrialized nations 
witnessed disproportionally increased trends in the prevalence of eczema, asthma, and 
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rhinitis [5, 9]. However, recent reports are indicating that a plateau in the prevalence has 
been reached in most of the countries that experienced increasing trends [10-12]. In 
contrast, countries with formerly low-prevalence are reporting increasing patterns in the 
prevalence and incidence of allergic disorders [10-13]. The disparity in the prevalence 
across nations and the changing trends over time within populations are indicators of the 
importance of environmental factors, in addition to the genetic elements, in disease 
pathogenesis. Deeper understanding of the natural history and risk factors of these 
chronic conditions will help us elucidate their plausible underlying etiological 
mechanisms. 
 
1.2 OVERALL STRUCTURE OF THE DISSERTATION 
This document is divided into six chapters, as the following: 
i. The first chapter provides background information on the dissertation topic, 
literature review relevant to the study questions, current gap in knowledge, and 
the specific aims and hypotheses of this study. 
ii. The second chapter explains in details the methodological parts of the study and 
the statistical analyses that were applied to achieve the goals of this dissertation. 
iii. Each of chapter three, four, and five is organized and formatted as a journal 
research report that have been or will be submitted for publication. Each of these 
three research-related chapters, also referred to as results chapters, represent one 
of the three specific aims of this dissertation. 
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iv. The sixth, last, chapter provides an overall synopsis and discussion of the results 
of the three research-related chapters and how results of these chapters are 
synthesized.  
 
1.3 LITERATURE REVIEW 
1.3.1 GLOBAL VARIATIONS IN THE PREVALENCE OF ALLERGIC DISORDERS 
Reports based on the ISAAC study revealed the existence of global variations and 
both between and within countries variations in the prevalence of allergic disorders [5, 
10, 11, 14, 15]. For instance, for the age group 6 to 7 years, data based on the ISAAC 
study showed that the 12-month prevalence of eczema ranged from 0.9% in India to 
22.5% in Ecuador [14]. For the age group 13 to 14 years, the prevalence of eczema 
between countries ranged from 0.2% in China to 24.6% in Columbia [14]. Similarly, the 
prevalence of asthma symptoms among 13 to 14 years old children ranged from 0.1% in 
Pune (India) to 16% in Costa Rica [16]. Prevalence of rhinitis showed even wider global 
variation, which ranged from 1% in India to 45.1% in Paraguay [17]. In addition to 
estimating the prevalence and time trends of allergic disorders, the ISAAC study allowed 
researcher to discover wide-range of geographical differences in the prevalence of 
eczema within countries. For example, the ISAAC phase 3 study was conducted in 10 
different locations across Spain, with the lifetime prevalence among 6 to 7 years olds 
being 35.6% in ‘A Coruna’ and 25.0% in ‘Barcelona’ [14]. Although the role of 
environmental factors in explaining the between and within countries variations in 
allergic disorders prevalence is essential, there is some strong evidence suggesting that 
genetic predisposition can potentiate the effects of environmental factors [18]. In 
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summary, both the between and within countries differences in the prevalence of allergic 
disorders are worth remarking as they can contribute to the advancement of etiologic 
research. 
 
1.3.2 NATURAL HISTORY OF ALLERGIC DISORDERS 
Eczema is an inflammatory skin disorder that is characterized by disrupted 
epidermal barrier function, immunoglobulin E (IgE)-mediated sensitization to food and 
environmental allergens (i.e., allergic sensitization), and a remitting–relapsing 
combination of skin dryness and itching [19-21]. Globally, the prevalence of eczema 
among children and adults has been estimated to be between 15% to 30% and 2% to 
10%, respectively, demonstrating wide variation across nations [20, 22]. The three major 
developmental periods of eczema are: infancy, childhood, and adolescence/adulthood; 
with 45% of all eczema cases occurring in the first 6 months of life [20, 23]. However, 
the long-term prognosis (natural history) of eczema is complex due to the relapsing and 
remitting nature of the disease. Emerging evidence is suggesting that eczema affects 
more boys during early life stages and becomes more predominant among adolescent 
girls and thereafter [20, 24]. Recently, we demonstrated that girls develop more eczema 
during puberty period while more boys outgrow their eczema [25]. Yet, more insights on 
the etiology of eczema are needed in order for preventable public-health efforts to 
succeed. 
Likewise, population-based studies have shown that the prevalence of both 
asthma and rhinitis is increasing and disproportionally affecting developed and 
developing countries [10]. Asthma, accounting for a substantial proportion of 
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burden/morbidity associated with allergic disorders, is a common chronic disorder 
affecting up to 25% of children and adults around the world [16, 26-29]. The major 
pathophysiological hallmarks that contribute to the complex heterogeneity of the clinical 
manifestations of asthma are recurrent airway inflammation, variable airway obstruction, 
and bronchial hyper-responsiveness [30, 31]. Similarly, an increase in the prevalence of 
rhinitis (10% to 30%), which is an inflammatory disease affecting the nasal tissue, has 
been documented during the last 30 years [32]. Common symptoms of rhinitis are nasal 
congestion and itching, sneezing, and rhinorrhoea, which negatively impact the quality of 
life [32, 33]. The natural history of both asthma and rhinitis is influenced by gender [34, 
35]. For asthma, a gender reversal occurs around the puberty period; the disorder 
predominantly affects boys before puberty, whereas, more girls are affected during 
adolescence and in early adulthood [26, 35-37]. However, the effect of gender on the 
long-term prognosis of rhinitis is further complicated by allergic sensitization (defined 
later) [33, 34]. 
Although it is acceptable to investigate the etiological mechanisms underlying 
allergic diseases separately; evidence supporting their comorbidity is increasing [38, 39]. 
Allergic comorbidity (coexistence) is defined as the concurrent presence of more than 
one allergic disorder (i.e. eczema, asthma, and rhinitis) in the same individual. The 
elevated comorbidity of asthma (lower-airway disorder) and rhinitis (upper-airways 
disorder) and their shared pathophysiology further support the concept of “one airway 
one disease” [12, 40]. In addition to the comorbidity of the allergic respiratory diseases, 
the concept of “allergic march” suggests that allergic diseases develop in a sequential 
pattern. Eczema is considered as the first step in the allergic march, usually developing 
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early in infancy/childhood followed by manifestations of allergic disorders of the airway 
later in childhood or early adolescence period [41]. The continuum developmental 
mechanism of allergic diseases is widely discussed in the scientific literature; however, 
supporting replicable evidence and high consensus is far from complete [41, 42]. Another 
revealing concept is the “coexistence” of allergic morbidities, which opposes the linear 
developmental pathway [42-44]. A report based on the German Multicenter Atopy Study 
(MAS), showed that eczema alone early in life does not support the allergic march, rather 
the coexistence of eczema and wheezing predicted asthma [45]. Such observation speaks 
in favor of the coexistence of allergic morbidities instead of a progressive development. 
The interrelationship between these conditions and the risk factors that either predispose 
individuals to follow the “allergic march” or “coexistence” remain an open field for 
research. 
 
1.3.3 ALLERGIC SENSITIZATION AND FILAGGRIN VARIANTS: AS COMMON RISK FACTORS 
A complex interplay between genetic, environmental, and immunological factors 
is considered to contribute to the pathogenesis of allergic disorders [43, 46]. Allergic 
sensitization, defined as the genetic susceptibility to produce Immunoglobulin E (IgE) 
antibodies in response to exposure to environmental or food antigens, is the most 
common thread linking the manifestations of allergic disorders [46-48]. Arshad et al 
suggested that 30% to 40% of cases of eczema, asthma, and rhinitis in early childhood 
can be attributed to allergic sensitization [49]. Yet, others suggested that up to 80% of 
asthmatic patients have concomitants allergic sensitization [50]. Similarly, it is well 
established that manifestations of eczema and rhinitis are closely associated with allergic 
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sensitization [23, 32, 46, 48]. Candidate-gene and genome-wide association studies have 
identified several genetic variants that are associated with the observed variability in IgE 
levels between allergic and non-allergic individuals [51, 52]. As a result, genetic factors 
that regulate the immune response dominated the research of allergic diseases for the last 
30 to 40 years.  
The recent discovery of loss-of-function variants in the filaggrin gene (FLG) 
caused a shift in the research paradigm from mainly focusing on immune related genes to 
incorporating genetic factors that regulate the formation of the epidermal barrier [53-55]. 
Filaggrin (filament-aggregating protein) is a key protein for the formation of functional 
skin barrier that inhibits the penetration of allergens, microbes, and irritants and limits 
transepidermal water loss [55-57]. Loss-of-function variants within the FLG are the 
strongest and most replicated risk factors for eczema development, yet [58, 59]. Filaggrin 
haploinsufficiency, i.e. reduction in filaggrin protein expression in heterozygous 
individuals, is associated with approximately 3-fold increased risk for eczema [60, 61]. It 
has been estimated that around 25% to 50% of eczema patients are carriers of at least one 
FLG variant, which is associated with an estimated population-attributable risk ranging 
from 4.2% to 15.2% [58, 61-63]. In addition to its association with eczema, multiple 
studies showed that FLG variants are associated with asthma and rhinitis [56, 60]. One 
school of thought considers that the association between FLG variants and asthma 
depends on the presence of eczema [59, 64, 65]. However, there is conflicting evidence 
as to whether the association between FLG variants and rhinitis is modified by eczema 
status [63, 64, 66]. To this end, it is clear that FLG variants are significant common 
thread for the development of the different allergic disorders. 
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1.3.4 DNA METHYLATION AND THE RISK OF ECZEMA 
The high heritability of eczema (71% to 84%), asthma (35% to 95%), and rhinitis 
(33% to 91%) and clustering within families demonstrate the importance of genetic 
predisposition in their pathogenesis [43, 67, 68]. However, thus far candidate-gene and 
genome-wide association studies have failed to explain the observed high heritability of 
allergic diseases. Hence, suggesting that genetic regulatory factors, other than DNA 
sequence variants, such as epigenetic variants may account for the unexplained genetic 
effect [69]. Epigenetic regulatory mechanisms are mitotically heritable and can alter gene 
activity without changing the DNA sequence [70]. DNA methylation, widely studied in 
epidemiological investigations due to practical and biological reasons [71, 72], along 
with histone modifications are important epigenetic marks that work hand-in-hand on 
influencing disease expression [73]. Since eczema is considered as the first manifestation 
of allergic disorders that can predispose to subsequent allergic morbidities, it is thus 
important to understand the epigenetic etiologic mechanisms that underlie eczema 
development. Up to our knowledge, the impact of DNA methylation on the risk of 
eczema has not been investigated previously. The epidermal differentiation complex 
(EDC), located on human chromosome 1q21, harbors a dense cluster of genes (including 
FLG) that are involved in the terminal differentiation of keratinocytes that are responsible 
for the integrity and functionality of the epidermal barrier [74-76]. Previous reports 
showed that a compromised epidermal barrier predispose to the development of eczema 
[77, 78]. Therefore, a comprehensive DNA methylation profiling of the EDC genomic 
region should provide novel insights into the epigenetic contribution in the development 
of eczema. 
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1.4 GAPS IN CURRENT STATE OF KNOWLEDGE 
Both, allergic sensitization (deviated immune response) and FLG variants 
(defective epidermal barrier) are important risk factors that link and predispose to the 
development of allergic disorders[46]. However, the current state of knowledge lacks 
clear understanding on the joint contribution of these two risk factors. Prior studies 
focused on eczema as the effect modifier for the association between FLG variants and 
asthma, while ignoring the role of allergic sensitization. Similarly, eczema was 
investigated as an effect modifier for the association between FLG variants and rhinitis, 
but not allergic sensitization. Furthermore, the single and joint role of FLG variants and 
allergic sensitization on the coexistence of allergic diseases (i.e., eczema, asthma, and 
rhinitis) has not been previously investigated. On the other hand, no existing knowledge 
on the role of epigenetic regulatory mechanisms (e.g., DNA methylation) of the EDC 
genomic loci that controls the epidermal barrier formation and functionality in relation to 
eczema risk is available. 
 
1.5 STUDY PROPOSAL, HYPOTHESES, AND AIMS 
Population-based longitudinal studies provide an unmatched opportunity to 
investigate the natural history of allergic disorders. Cross-sectional and case-control 
studies lack the ability of determining the longitudinal effect of risk factors on outcomes. 
However, follow-up studies with repeated measurements of the outcomes of interest (e.g., 
eczema, asthma, and rhinitis) and risk factors (e.g., allergic sensitization) facilitate the 
determination of whether the effects are established early or later in the development of 
diseases. Furthermore, we can determine whether the effect of time-independent risk 
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factor (e.g. FLG variants) changes over-time. In contrast, for dynamic (time-varying) risk 
factors (e.g., allergic sensitization) determining their concurrent effects allow the risk to 
change over-time. This dissertation aims at enhancing our understanding of the role of 
FLG variants, allergic sensitization, and epigenetic modifications on the development of 
allergic diseases, by examining the following specific hypotheses (H): 
H1: Allergic sensitization, not eczema, is the main effect modifier of the association 
between FLG variants and asthma. 
H2: The association between FLG variants and rhinitis is modified by allergic 
sensitization status, not eczema status. 
H3: FLG variants and allergic sensitization jointly increase the risk of having single and 
multiple (coexisting) allergic disorders. 
H4: Eczema-affected and eczema-free individuals have different DNA methylation 
profiles for the EDC genomic region. 
Hypothesis 1, 2, and 3 will be tested using data from the Isle of Wight 1989 birth 
cohort study (n = 1,456). Participants were prospectively followed-up at the ages of 1, 2, 
4, 10, and 18 years. Hypothesis 4 will be tested in a subset (n = 367) of Isle of Wight 
birth cohort participants that had DNA methylation measurements. For the purpose of 
validation, hypothesis 4 will be further tested in two semi-independent samples (pregnant 
cohort participant, their partners, and their offspring, the F2 generation). The specific 
aims (SA) of this dissertation are: 
SA1: To determine the magnitude of modification imposed by eczema and allergic 
sensitization on the association between “FLG variants and asthma” (H1). 
Similarly, I will determine whether eczema and/or allergic sensitization act as an 
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effect modifier for the association between “FLG variants and rhinitis” (H2). 
Overall, I will test whether the combined (joint) effect of two risk factors (i.e., 
“FLG variants and eczema” or “FLG variants and allergic sensitization”) yields 
higher risk of asthma (or rhinitis).  
SA2: To test whether FLG variants and allergic sensitization jointly predispose to the 
comorbidity of eczema, asthma and rhinitis (H3). 
SA3: To associate DNA methylation across the EDC genomic region with eczema status 
(H4). 
 
1.6 HOW WOULD RESULTS OF THIS DISSERTATION ENHANCE OUR KNOWLEDGE? 
Better understanding of the genetic and epigenetic contribution to the 
development of allergic diseases will be gained by successfully accomplishing the 
specific aims of this dissertation. We have previously shown that the combined effect of 
allergic sensitization and FLG variants predisposed individuals at higher risk of having 
concurrent and subsequent eczema [79]. In this dissertation, I will investigate whether 
allergic sensitization (or eczema) in combination with FLG variants increase the risk of 
having concurrent and subsequent asthma and rhinitis. The current knowledge indicates 
that FLG variants increase the risk of asthma only in the presence of eczema [59, 66]; 
however, I propose to test whether allergic sensitization is the effect modifier rather than 
eczema. Furthermore, the current inconsistencies in the associations between FLG 
variants and rhinitis can be attributed to the failure of previous studies in accounting for 
the possible interaction between FLG variants and allergic sensitization on the risk of 
rhinitis. Therefore, SA1 of this dissertation will enhance our knowledge by showing that 
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allergic sensitization is the main effect modifier of the association between FLG variants 
and asthma and FLG variants and rhinitis. 
Results of SA1 of this dissertation will show the importance of FLG variants and 
allergic sensitization on the development of single allergic disorders (i.e., asthma and 
rhinitis). In contrast, SA2 sought to determine whether FLG variants and allergic 
sensitization are associated with the coexistence of multiple allergic diseases rather than a 
single morbidity. Previous etiologic research in the field of allergic comorbidities is 
highly limited and assessments of the joint role of allergic sensitization and FLG variants 
on the development of allergic comorbidities is lacking. Therefore, results of SA2 will 
enhance our understanding of the underlying risk factors that predispose individuals at 
higher risk of having multiple allergic disorders. 
In addition to the role of genetic variants in the pathogenesis of allergic diseases, 
the etiologic role of epigenetic modifications (e.g., DNA methylation) is rapidly 
emerging and scientifically sound. Recently we showed a significant interaction between 
FLG variants and adjacent differential DNA methylation on the risk of eczema [80]. 
Results of this report suggested that the association between FLG variants and eczema is 
modulated by DNA methylation. Recent evidence is suggesting that epigenetic 
mechanisms, such as DNA methylation, that alter gene activity without changing the 
underlying DNA sequence account for a considerable amount of the unexplained genetic 
effect found in complex diseases, such as eczema [69, 72]. In this dissertation I propose 
going beyond the single-gene approach (i.e., FLG gene) into incorporating the DNA 
methylation of the EDC locus at chromosome 1q21 (SA3). The EDC includes a dense 
cluster of approximately 60 genes (including FLG) encoding structural and regulatory 
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proteins that are essential for keratinocyte differentiation [76, 81, 82]. Comprehensively 
analyzing DNA methylation status of the EDC genomic region will provide novel 
insights, beyond genetic variants, on the contribution of epigenetic modifications. 
Therefore, I anticipate that DNA methylation of the EDC will further show the 
importance of this genomic region for the development of eczema. SA3 will focus on 
eczema since it is considered the first manifestation of allergic diseases. The ultimate 
goal of this dissertation is to improve our ability of characterizing and classifying 
susceptible individuals, which will lead to an improved clinical management and the 
development of efficient intervention and prevention strategies. 
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CHAPTER 2 
METHODS 
2.1 STUDY DESIGN AND PARTICIPANTS 
 This dissertation is mainly based on information collected from the Isle of Wight 
(IOW) birth cohort. An unselected population-based study (n = 1,536) was recruited 
between January 1989 and February 1990 in the Isle of Wight, United Kingdom, to 
prospectively study the natural history and etiology of asthma and allergic diseases. The 
island is close to the British mainland, semi-rural, without heavy industry. Both the Isle 
of Wight and the study populations are 99% Caucasian. After excluding adoptions, 
perinatal deaths, and refusals for follow-up, written informed consent was obtained from 
parents to enrol 1,456 children (95%), with follow-up assessments conducted at ages 1 (n 
= 1,167), 2 (n = 1,174), 4 (n = 1,218), 10 (n = 1,373), and 18 (n = 1,313) years. Ethics 
approvals were obtained from the Isle of Wight Local Research Ethics Committee (now 
named the National Research Ethics Service, NRES Committee South Central – 
Southampton B) at recruitment and for the 1, 2, 4, 10 and 18 years follow-ups 
(06/Q1701/34). Detailed questionnaires were completed for each child at each follow-up. 
When a visit was not possible, a telephone questionnaire was completed or a postal 
questionnaire sent for completion and return. 
 For the purpose of testing H4, a subsample (discovery cohort: n = 367, aged 18 
years) of the IOW birth cohort participants were randomly selected for epigenetic study. 
We also considered two cohorts to test the reproducibility of results obtained from the 
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discovery cohort. Replication cohort I (n = 146; parents of the F2 generation) includes 
participants of the IOW cohort (28.8% were part of the discovery cohort) plus new 
participants. Expecting mothers and their partners were assessed before delivery. 
Replication cohort II (n = 94; F2 generation) includes the F2 newborns of the IOW cohort 
participants plus new parents. Infants were followed-up at ages 3-, 6-, and 12-months. 
 
2.2 PHENOTYPES 
 In all assessments of the Isle of Wight birth cohort, eczema was defined as 
chronic or chronically relapsing, itchy dermatitis lasting more than 6 weeks with 
characteristic morphology and distribution [83], following Hanifin and Rajka criteria 
[84]. For asthma, at the 1, 2, and 4-year follow-ups, the medical investigator determined 
the presence of asthma based on wheeze frequency over the last 12 months and treatment 
given for asthma or asthma related symptoms. At the 10 and 18 year follow-ups, asthma 
was defined as having “ever had asthma” and either “wheezing or whistling in the chest 
in the last 12 months” or “current treatment for asthma”, using ISAAC questionnaire [4]. 
Rhinitis was defined by a positive response to: ‘In the past 12 months have you had a 
problem with sneezing, or a runny or a blocked nose when you did not have a cold or the 
flu?’ [33]. Since the 1-year and 2-year follow-up data on eczema, asthma, and rhinitis 
were collected in a relatively small time window, we combined them for analytic 
purposes (reported as 1-or-2 years). 
 To determine allergic sensitization status, skin prick testing (SPT) at ages 1 and 2 
years was performed on children with any symptoms of eczema, asthma, or rhinitis. We 
combined SPT results for ages 1 and 2 years, since they occurred within a short time 
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period and will henceforth refer to this as SPT at 1-or-2 years. At 4, 10 and 18 years, 
regardless of symptoms, SPT was performed on most children attending the research 
center to a standard battery of common allergens (ALK-Albello, Horsholm, Denmark). 
Inhalant allergens tested were house dust mite, cat, dog, Alternaria alternata, 
Cladosporium herbarium, grass pollen mix, and tree pollen mix. Food allergens tested 
were cows’ milk, soya, hens’ egg, peanut and cod. Positive and negative controls were 
included. Allergic sensitization was defined by having a SPT to at least one allergen test 
with mean wheal diameter of 3 mm greater than the negative control. Since allergic 
sensitization is a dynamic rather than a completely stable phenotype, we used the 
concurrent status and thus allowed the risk to change over time. 
 
2.3 FLG GENOTYPING 
 DNA was extracted from blood or saliva samples from cohort subjects (n = 
1,211). Five variants in the FLG gene that result in loss of function and are reported to be 
common in populations of European ancestry were selected for genotyping [79]. DNA 
samples were interrogated using GoldenGate Genotyping Assays (Illumina, Inc, 
SanDiego, CA) on the BeadXpressVeracode platform (Illumina, Inc, SanDiego, CA) per 
Illumina’s protocol. In brief, samples were fragmented and hybridized to the pool of 
allele-specific primer sets. Following an extension/ligation reaction the samples were 
then hybridized to the Veracode bead pool and processed on the BeadXpress reader. Data 
were analyzed using the genotyping module of the GenomeStudio Software package 
(Illumina, Inc, SanDiego, CA). DNA from each subject plus 37 replicate samples were 
analyzed for a total of 1,248 samples. The quality threshold for allele determination was 
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set at a GenCall score > 0.25 (scores ≤ 0.25 were “no calls”) with n = 1,227 samples 
(98.3%) retained for further analysis. Analysis of each locus included reclustering of 
genotyping data using our project data to define genotype cluster positions with 
additional manual reclustering to maximize both cluster separation and the 50th 
percentile of the distribution of the GenCall scores across all genotypes (50% GC score). 
Children were classified as having FLG loss-of-function defect if they carry the minor 
allele for at least one of the following FLG null variants: R501X, 2282del, or S3247X. 
Variants 3702delG and R2447X were not informative in our population due to minor 
allele frequencies being < 0.1% [79], and thus were not used in defining filaggrin 
haploinsufficiency.  
 
2.4 DNA METHYLATION PROFILING 
DNA was extracted from whole blood collected at age 18 years (discovery cohort), whole 
blood of replication cohort I participants’, and cord blood of replication cohort II 
participants’ [85], and bisulfite-treated for cytosine to thymine conversion using the EZ 
96-DNA methylation kit (Zymo Research, CA, USA). Genome-wide DNA methylation 
was assessed using the Illumina Infinium HumanMethylation450 BeadChip (Illumina, 
Inc., CA, USA), which interrogates > 484,000 CpG sites associated with approximately 
24,000 genes. Arrays were processed using a standard protocol [86]. The BeadChips 
were scanned using a BeadStation, and the methylation level (beta value) calculated for 
each queried CpG locus using the Methylation Module of BeadStudio software. After 
cleaning of the DNA methylation data, beta (β) values presented as the proportion of 
methylated (M) over methylated (M) and unmethylated (U) sites (β=M/[c+M+U], with c 
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being constant to prevent dividing by zero) were used to estimate the effect of DNA 
methylation [87]. 
 
2.5 STATISTICAL ANALYSIS 
Statistical analyses and approach for each of the three specific aims will be presented 
separately. 
 
2.5.1 SPECIFIC AIM 1: STATISTICAL ANALYSIS 
SA1: To determine the magnitude of modification imposed by eczema and allergic 
sensitization on the association between “FLG variants and asthma” (H1). 
Similarly, I will determine whether eczema and/or allergic sensitization act as an 
effect modifier for the association between “FLG variants and rhinitis” (H2). 
Overall, I will test whether the combined (joint) effect of two risk factors (i.e., 
“FLG variants and eczema” or “FLG variants and allergic sensitization”) yields 
higher risk of asthma (or rhinitis).  
 For all of the association analyses that will be performed to approach SA1, log-
binomial (log linear) regression models will be applied to estimate risk ratios (RRs) and 
their 95% confidence intervals (95% CIs) using the GENMOD procedure in SAS 9.3 
(SAS, Gary, NC, USA). Since the proposed effect modifiers (i.e., allergic sensitization 
and eczema) and the two outcomes (i.e., asthma and rhinitis) were measured repeatedly at 
ages 1-or-2, 4, 10, and 18 years, the generalized estimating equations (GEE) method will 
be used, which accounts for the correlated observations and the within-child effect by 
employing a covariance matrix solved through an iterative estimating process based on a 
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working correlation matrix [88]. The appropriate working correlation matrix will be 
determined by using the Akaike information criterion (AIC).  
 In an explanatory step, to determine whether the RRs of the association of FLG 
variants with asthma and rhinitis differ according to the presence or absences of the 
proposed effect modifiers, we evaluated the association in the total study sample and sub-
samples based on the status of the possible effect modifiers. Next, interaction terms, on a 
multiplicative scale, were used to test the additional effect of two co-occurring risk 
factors on the health outcomes above and beyond their individual effects. Also, to 
evaluate whether the effect of FLG variants across levels of the effect modifiers were 
statistically significantly different, we included interaction terms in separate regression 
models (model 1: FLG variants × eczema and model 2: FLG variants × allergic 
sensitization). To decipher which interactive effect was more pronounced, a regression 
model including both interaction terms (model 3: FLG variants × eczema and FLG 
variants × allergic sensitization) was evaluated. Henceforth, we refer to models 1, 2, and 
3 as the ‘concurrent models’ since the effect modifiers and the outcomes coexisted at the 
same time. In the case of a possibly statistically significant interaction term (Pinteraction < 
0.1), the “combined effect”, referring to the joint impact of two individual risk factors 
plus their interaction on the occurrence of the outcome, was estimated as follows: RR = 
exp[(β1 × allergic sensitization) + (β2 × FLG variants) + (β3 × allergic sensitization × 
FLG variants)]. We repeated the previous analyses while stratifying by sex to determine 
if sex-specific effects existed. In all GEE models, sex and age at follow-up were included 
as potential confounders.  
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 In addition to the concurrent models, we tested the interactions in ‘delayed effect’ 
models to investigate whether the time-order of risk and response supports the concurrent 
model findings. The delayed effect analysis helps to determine whether the interaction 
effects contribute to the developmental process of asthma and rhinitis. To this end, we 
analyzed whether FLG variants interact with preceding allergic sensitization or eczema 
on the risk of subsequent asthma and rhinitis. For example, the interaction of FLG 
variants with allergic sensitization status at age 1-or-2 years on the risk of asthma at age 4 
years (FLG variants × SPT results at 1-or-2 years  asthma at 4 years) was evaluated. 
The prevalence of the clinical phenotype (e.g., asthma at 4), which was used in the 
delayed effect models, included new occurrences and persistence of the disease. 
Therefore, we constructed three delayed periods (1-or-2 to 4 years, 4 to 10 years, and 10 
to 18 years) to determine if the presence of both FLG variants and preceding allergic 
sensitization or preceding eczema influences the positive transition, defined as the change 
in disease status from disease-free to diseased, and the persistence of the disease in two 
consecutive follow-ups. 
 
2.5.2 SPECIFIC AIM 2: STATISTICAL ANALYSIS 
SA2: To test whether FLG variants and allergic sensitization jointly predispose to the 
comorbidity of eczema, asthma and rhinitis (H3). 
 Information on eczema, asthma, and rhinitis were collected prospectively at ages 
1-or-2, 4, 10, and 18 years from the IOW study participants. For each age I will create a 
new variable that has 8 categories, which identifies all the possible combinations of 
allergic comorbidities at the respective follow-up (Table 2.1). This type of categorization 
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will allow us to have better understanding on the prevalence of each allergic category at 
the different ages. 
Table 2.1. Categories of allergic comorbidities 
No Disease 
Rhinitis 
Asthma 
Eczema 
Eczema + Asthma 
Eczema + Rhinitis 
Asthma + Rhinitis  
Eczema + Asthma + Rhinitis 
 To estimate the single and combined effects of the risk factors, FLG variants and 
repeated measures of allergic sensitization, on allergic disorders, generalized estimating 
equations (GEE) were used when estimating the covariance matrix to account for 
correlated observations and the within-child effect of the repeated measurements [88]. 
Risk ratios (RR) and their 95% confidence intervals (95% CIs) were estimated by 
applying log-binomial regression models using the GENMOD procedure in SAS 9.3 
(SAS, Gary, NC, USA). The “no allergic disorder” category formed the reference 
category. The main effects of FLG variants and allergic sensitization on the risk for 
single allergic disorders and comorbidities were estimated separately (single risk factor 
models). In a full model, the two main plus their interaction effect (FLG variants × 
allergic sensitization) were estimated. We repeated the aforementioned analysis while 
excluding the 1-or-2 years follow-up data from the GEE analysis to estimate whether 
possible misclassifications of phenotypes at early life biased our results. In the case of a 
possibly statistically significant interaction (Pinteraction < 0.1), the combined effect was 
estimated as follows: RR = exp[(β1 × allergic sensitization) + (β2 × FLG variants) + (β3 
× allergic sensitization × FLG variants)]. The term ‘combined effect’ was used to 
22 
describe the joint impact of two individual risk factors plus their interaction on the 
occurrence of the outcome. In all GEE models, sex and age at follow-up were included as 
potential confounders. To evaluate statistical significance of main effects of covariates 
(not interaction terms), a P-value ≤ 0.05 was used as indicator of statistical significance. 
 To determine the proportion of the different allergic morbidities/comorbidities 
related to FLG variants and allergic sensitization, population attributable fractions (PAFs) 
were estimated using the following formula: PAF = pc × [(RR – 1)/RR], where pc is the 
proportion of diseased-individuals that are exposed [89, 90]. This approach yields valid 
PAF estimates in the presence of confounding and/or effect modification, only when 
using adjusted RRs [89, 90]. In case of statistically significant interactions between 
allergic sensitization and FLG variants, the RRs for the combined effect were used to 
estimate PAFs associated with both risk factors. If no interaction was detected, adjusted 
RRs were used to estimate separate PAFs for each of the two risk factors and an overall 
PAF was obtained using the following formula: PAFoverall = 1 – [(1 – PAFallergic sensitization) 
× (1 – PAFFLG variants)] [89]. 
 
2.5.3 SPECIFIC AIM 3: STATISTICAL ANALYSIS 
SA3: To associate DNA methylation across the EDC genomic region with eczema status 
(H4). 
 Although genome-wide DNA methylation profiles were available, I restricted the 
analysis to 256 CpG sites that span the EDC genomic region (location on human 
chromosome 1: 151958685 – 153628983). After performing quality control measures on 
DNA methylation data, Beta-values presented as the proportion of methylated (M) over 
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methylated (M) and unmethylated (U) sites (Beta-value = M/[c+M+U], with c being 
constant to prevent dividing by zero) were calculated for each CpG site [87]. Beta-values 
provide intuitive biological interpretation (i.e., % methylation); however, (i) being 
constrained between values of 0 (unmethylated) and 1 (completely methylated) and (ii) 
demonstrating high heteroscedasticity in the lower and upper ends of the methylation 
range has raised concerns on the validity of this measure when performing statistical 
analysis [91]. The conversion of Beta-values to M-values (M-value = log2(Beta-value/[1 – 
Beta-value]) has been shown to overcome the limitations of beta-values [91]. Moreover, 
the use of M-values, when performing statistical analysis, demonstrated increased 
reliability in terms of detecting differentially methylated CpG sites; however, M-values 
cannot be directly interpreted [91, 92]. Therefore, following previous recommendation 
[91], we used M-values when performing the statistical analysis and reported the statistics 
at the scale of Beta-values. 
 All statistical analyses were conducted using SAS® version 9.3 (SAS Institute, 
Cary, NC, USA). In the discovery cohort, linear regression was used to test the 
association between DNA methylation (M-values) of all CpG sites spanning the EDC 
region with eczema status adjusting for sex and cell-type composition. To minimize 
false-positive findings identified in 256 models, CpG sites with a false discovery rate 
(FDR) adjusted p-value < 0.1 were selected and considered as potentially associated with 
eczema. The selected CpG sites, in the discovery cohort, were taken forward and tested 
for their possible association with eczema status in replication cohorts I and II. Then, the 
selected CpG sites were tested for association with eczema in males and females 
separately. 
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CHAPTER 3 
RESULTS I 
 
MANUSCRIPT # 1: ASSOCIATION OF FILAGGRIN VARIANTS WITH ASTHMA AND RHINITIS: IS 
ECZEMA OR ALLERGIC SENSITIZATION STATUS AN EFFECT MODIFIER?1 
                                                           
1 A. H. Ziyab, W. Karmaus, J. W. Holloway, H. Zhang, S. E. Steck, S. Ewart, S. H. 
Arshad. Submitted to International Archives of Allergy and Immunology, 12/4/2013. 
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3.1 ABSTRACT 
Background: Association of filaggrin (FLG) variants with asthma and rhinitis have 
shown to be modulated by eczema status. However, it is unknown whether allergic 
sensitization status modifies this association. The aim of this study was to determine 
whether FLG variants need eczema and/or allergic sensitization as a necessary 
component to execute its adverse effect on coexisting and subsequent asthma and rhinitis. 
Methods: Repeated measurements of asthma, rhinitis, eczema, and allergic sensitization 
(documented by skin prick tests) at ages 1, 2, 4, 10, and 18 years were ascertained in the 
Isle of Wight birth cohort (n = 1,456). FLG haploinsufficiency was defined as having at 
least the minor allele of R501X, 2282del4, or S3247X variants. Log binomial regression 
models were used to test associations and statistical interactions. 
Results: FLG variants increased the risk of asthma (RR = 1.39, 95% CI: 1.06 – 1.80) and 
rhinitis (RR = 1.37, 95% CI: 1.16 – 1.63). In delayed effect models, ‘FLG variants plus 
allergic sensitization’ and ‘FLG variants plus eczema’ increased the risk of subsequent 
asthma by 4.93-fold (95% CI: 3.61 – 6.71) and 3.33-fold (95% CI: 2.45 – 4.51), 
respectively, during the first 18 years of life. In contrast, neither eczema nor allergic 
sensitization in combination with FLG variants increased the risk of later rhinitis. 
Conclusions: Allergic sensitization and eczema modulated the association between FLG 
variants and asthma, but not rhinitis. Results of our study imply that the mechanisms and 
pathways through which FLG variants predispose to increased risk of asthma and rhinitis 
may be different. 
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3.2 INTRODUCTION 
The burden associated with allergic disorders, including eczema, asthma, and 
rhinitis is substantial and of public health importance. Prior investigations indicated that a 
complex interplay between genetic, immunological, and environmental factors 
contributes to the development and maintenance of such allergic manifestations. Until 
recently, etiologic research focused on the role of immune dysregulation in the 
pathogenesis of allergic disorders; however, a shift in the research paradigm towards 
understanding the contribution of a defective epidermal barrier rapidly emerged after the 
discovery of loss-of-function variants in the filaggrin gene (FLG) [53, 56, 60]. Filaggrin 
haploinsufficiency, defined as partial or complete loss of filaggrin (filament-aggregating 
protein) protein, is associated with the development of an impaired epidermal barrier that 
is characterized by increased allergen penetration and water permeability [93].  
Thus far, FLG variants are the most replicated and strongest genetic risk factor for 
eczema [59]. Also, FLG variants are considered to be associated with asthma and rhinitis 
[66]. Of importance is that the association between FLG variants and asthma is stronger 
in the presence of eczema [59, 66]. However, this possible effect modification by eczema 
was not demonstrated for the association between FLG variants and rhinitis [66]. 
Mechanisms that underlie the association of FLG variants with asthma and rhinitis are 
not well understood since FLG is not expressed in the upper or lower airway epithelium 
[94, 95]. A proposed pathway is that cutaneous sensitization, facilitated by FLG variants, 
may lead to local and systematic inflammation at distant organs (i.e., lung and nasal 
tissues) [56, 60].  
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While the concept that eczema leads to asthma in children who have a loss-of-
function variants in the FLG gene is attractive, research in this area has neglected the role 
of allergic sensitization, defined as the propensity to produce immunoglobulin E (IgE) 
antibodies responses to environmental and food antigens [96]. Only one study based on 
the German Multicenter Allergy Study (MAS) birth cohort addressed allergic 
sensitization and reported an interaction between FLG variants and food sensitization in 
the pathogenesis of asthma among children with eczema [97]. Hence, further 
investigations on whether the associations of FLG variants with asthma and rhinitis are 
modified by eczema and/or allergic sensitization are needed so that preventive efforts can 
be directed to either clinical management of eczema or allergic sensitization or both. 
We hypothesized that allergic sensitization, rather than eczema status, modifies 
the association of FLG variants with asthma and rhinitis. Therefore, statistical 
interactions (FLG variants × allergic sensitization and FLG variants × eczema) were 
tested to determine whether FLG variants plus allergic sensitization and/or FLG variants 
plus eczema jointly increased the risk of asthma and/or rhinitis. To this end, analyzing 
longitudinal data from the Isle of Wight birth cohort covering childhood and adolescence 
prospectively enabled us to determine whether FLG variants need allergic sensitization or 
eczema as a necessary component to execute its adverse effect on coexisting and 
subsequent asthma and rhinitis. 
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3.3 METHODS 
3.3.1 STUDY DESIGN AND PARTICIPANTS 
An unselected whole population birth cohort (n = 1,536) was recruited in 1989 in 
the Isle of Wight, UK, to prospectively study the natural history of allergic conditions. 
After exclusion of adoptions, perinatal deaths, and refusal for follow-up, 1,456 (95%) 
children were enrolled, with follow-up assessments conducted at 1, 2, 4, 10, and 18 years 
of age. Ethics approvals were obtained from the Isle of Wight Local Research Ethics 
Committee (NRES Committee South Central – Southampton B) at recruitment and for 
the subsequent follow-ups (06/Q1701/34). At each follow-up, validated questionnaires, 
including the International Study of Asthma and Allergy in Childhood (ISAAC) 
questionnaire [4], were completed on allergic disorders plus demographic attributes and 
exposures to environmental factors. 
 
3.3.2 PHENOTYPES 
In all assessments of the Isle of Wight birth cohort, eczema was defined as 
chronic or chronically relapsing, itchy dermatitis lasting more than 6 weeks with 
characteristic morphology and distribution [83], following Hanifin and Rajka criteria 
[84]. For asthma, at the 1, 2, and 4-year follow-ups, the medical investigator determined 
the presence of asthma based on wheeze frequency over the last 12 months and treatment 
given for asthma or asthma related symptoms. At the 10 and 18 year follow-ups, asthma 
was defined as having “ever had asthma” and either “wheezing or whistling in the chest 
in the last 12 months” or “current treatment for asthma”, using ISAAC questionnaire [4]. 
Rhinitis was defined by a positive response to: ‘In the past 12 months have you had a 
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problem with sneezing, or a runny or a blocked nose when you did not have a cold or the 
flu?’ [33] Since the 1-year and 2-year follow-up data on eczema, asthma, and rhinitis 
were collected in a relatively small time window, we combined them for analytic 
purposes (reported as 1-or-2 years). 
To determine allergic sensitization status, skin prick testing (SPT) at ages 1 and 2 
years was performed on children with any symptoms of eczema, asthma, or rhinitis. We 
combined SPT results for ages 1 and 2 years since they occurred within a short time 
period and will henceforth refer to this as SPT at 1-or-2 years. At 4, 10, and 18 years, 
regardless of symptoms, SPT was performed on most children attending the research 
center to a standard battery of common allergens (ALK-Albello, Horsholm, Denmark). 
Inhalant allergens tested were house dust mite, cat, dog, Alternaria alternata, 
Cladosporium herbarium, grass pollen mix, and tree pollen mix. Food allergens tested 
were cows’ milk, soya, hens’ egg, peanut and cod. Positive and negative controls were 
included. Allergic sensitisation was defined by having a positive SPT to at least one 
allergen test with mean wheal diameter of 3 mm greater than the negative control. Since 
allergic sensitization is a dynamic rather than a completely stable phenotype, we used the 
concurrent and/or preceding status and thus allowed the risk to change over time. 
 
3.3.3 FLG GENOTYPING 
Blood and/or saliva samples were collected at ages 10 and/or 18 years from which 
genomic DNA was isolated. DNA samples were interrogated using GoldenGate 
Genotyping Assays (Illumina, Inc, SanDiego, CA) on the BeadXpressVeracode platform 
(Illumina, Inc, SanDiego, CA) per Illumina’s protocol. Individuals carrying the minor 
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allele for at least one of the FLG variants R501X, 2282del4, or S3247X were classified as 
having filaggrin haploinsufficiency. The R2447X variant was also genotyped, but none of 
the study participants carried the minor allele. Detailed information on genotyping is 
provided by Ziyab et al. [79]. 
 
3.3.4 STATISTICAL ANALYSIS 
Since the proposed effect modifiers (i.e., allergic sensitization and eczema) and 
the two outcomes (i.e., asthma and rhinitis) were measured repeatedly at ages 1-or-2, 4, 
10, and 18 years, we applied the generalized estimating equation (GEE) method with 
first-order autoregressive covariance matrix to account for the correlated observations 
and the within-child effect of the repeated measurements [88]. Risk ratios (RR) and their 
95% confidence intervals (95% CIs) were estimated by applying log-binomial regression 
models using the GENMOD procedure in SAS 9.3 (SAS, Gary, NC, USA). To determine 
whether the RRs of the association of FLG variants with asthma and rhinitis differ 
according to the presence or absences of the proposed effect modifiers, we evaluated the 
association in the total study sample and sub-samples based on the status of the possible 
effect modifiers. 
Interaction terms, on a multiplicative scale, were used to test the additional effect 
of two co-occurring risk factors on the health outcomes above and beyond their 
individual effects. Also, to evaluate whether the effect of FLG variants across levels of 
the effect modifiers were statistically significantly different, we included interaction 
terms in separate regression models (model 1: FLG variants × eczema and model 2: FLG 
variants × allergic sensitization). To decipher which interactive effect was more 
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pronounced, a regression model including both interaction terms (model 3: FLG variants 
× eczema and FLG variants × allergic sensitization) was evaluated. Henceforth, we refer 
to models 1, 2, and 3 as the ‘concurrent models’ since the effect modifiers and the 
outcomes coexisted at the same time. In the case of a possibly statistically significant 
interaction term (Pinteraction < 0.1), the “combined effect”, referring to the joint impact of 
two individual risk factors plus their interaction on the occurrence of the outcome, was 
estimated. We repeated the previous analyses while stratifying by sex to determine if sex-
specific effects existed. In all GEE models, sex and age at follow-up were included as 
potential confounders. 
In addition to the concurrent models, we tested the interactions in ‘delayed effect’ 
models to investigate whether the time-order of risk and response supports the concurrent 
model findings. The delayed effect analysis helps to determine whether the interaction 
effects contribute to the developmental process of asthma and rhinitis. To this end, we 
analyzed whether FLG variants interact with preceding allergic sensitization or eczema 
on the risk of subsequent asthma and rhinitis. For example, the interaction of FLG 
variants with allergic sensitization status at age 1-or-2 years on the risk of asthma at age 4 
years (FLG variants × SPT results at 1-or-2 years  asthma at 4 years) was evaluated. 
The prevalence of the clinical phenotype (e.g., asthma at 4), which was used in the 
delayed effect models, included new occurrences and persistence of the disease. 
Therefore, we constructed three delayed periods (1-or-2 to 4 years, 4 to 10 years, and 10 
to 18 years) to determine if the presence of both FLG variants and preceding allergic 
sensitization or preceding eczema influences the positive transition, defined as the change 
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in disease status from disease-free to diseased, and the persistence of the disease in two 
consecutive follow-ups [37]. 
 
3.4 RESULTS 
3.4.1 DESCRIPTION OF STUDY POPULATION 
Of the 1,456 children enrolled in the study, 1,377 were followed-up at age 1-or-2 
years, 1,214 at 4 years, 1,368 at 10 years, and 1,309 at 18 years. The period prevalence 
ranged between 11.9% to 14.2% for eczema, 14.3% to 17.7% for asthma, and 5.6% to 
35.8% for rhinitis (table 3.1). At age 1-or-2 years, SPTs were performed on symptomatic 
children (n = 515), of which 20.6% had at least one positive SPT response. At all other 
ages, the majority of participates underwent SPTs with the proportion of positive SPTs 
being 19.4% at 4 years, 26.9% at 10 years, and 41.4% at 18 years of age. Genotype 
frequencies of FLG variants (table 3.1) were concordant with Hardy-Weinberg 
equilibrium. 
 
3.4.2 FLG VARIANTS AND ASTHMA 
In the total study sample, FLG variants increased the risk of repeated occurrence 
of asthma from 1-or-2 to 18 years of age (RR = 1.39, 95% CI: 1.06 – 1.80; figure 3.1). In 
the presence of eczema, the effect size increased (RR = 1.56, 95% CI: 1.10 – 2.21); in the 
absence of eczema, the magnitude of the association between FLG variants and asthma 
was reduced and lost statistical significance (RR = 1.26, 95% CI: 0.93 – 1.69). This 
association was noticeably modified when stratifying based on the presence (RR = 1.49, 
33 
95% CI: 1.14 – 1.94) or absence (RR = 0.76, 95% CI: 0.48 – 1.21) of allergic 
sensitization.  
To determine whether the observed differences in the associations were 
statistically significant, statistical interactions on a multiplicative scale were evaluated in 
concurrent models. There was no evidence for an interaction between FLG variants and 
eczema on the risk for asthma (interaction effect RR = 1.18, 95% CI: 0.78 – 1.79, 
Pinteraction = 0.429; figure 3.1). However, a statistically significant interaction was found 
between FLG variants and allergic sensitization on the risk for asthma (interaction effect 
RR = 2.00, 95% CI: 1.22 – 3.28, Pinteraction = 0.006; figure 3.1). The combined effect of 
FLG variants and allergic sensitization increased the risk of asthma by 3.63-fold (95% 
CI: 2.81 – 4.70). Furthermore, to determine which interactive effect is more important, 
we simultaneously included both interaction terms in one regression model. Results 
showed that the interaction between FLG variants and allergic sensitization remained 
statistically significant after adjusting for the interactive effect between FLG variants and 
eczema (data not shown). However, the latter did not gain statistical significance.  
We retested the results of the aforementioned concurrent models, using delayed 
effect models. In these models we used the preceding cumulative SPTs results (or eczema 
status), i.e. all SPTs results (or eczema status) from assessments that are prior to the 
outcome assessment, when testing the interaction between FLG variants and allergic 
sensitization (or eczema) on the risk of subsequent asthma. The results of the delayed 
effect models show that the combined effect of preceding allergic sensitization with FLG 
variants increased the risk of asthma in the next exam at each delay period (figure 3.2a). 
For instance, the presence of both FLG variants plus positive SPT at 1-or-2 and/or 4 years 
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increased the risk of asthma at 10 years (RR = 7.22, 95% CI: 4.84 – 10.80). Although 
results of the concurrent model (figure 3.1) did not show an interaction between FLG 
variants and eczema, the delayed effect models demonstrated interactive effects between 
FLG variants and preceding eczema on the risk of subsequent asthma (figure 3.2b). The 
repeated measurement analysis shows that the combined effect of FLG variants and 
preceding eczema, on average, increased the risk of later asthma during the first 18 years 
of life (RR = 3.33, 95% CI: 2.45 – 4.51). 
To further understand whether the observed interactions between FLG variants 
and preceding allergic sensitization and eczema influence new occurrence and/or 
persistence of asthma, we calculated the proportions of positive transitions (defined as the 
change in disease status from disease-free to diseased in two consecutive follow-ups) and 
persistence among those with and without both risk factors (table 3.2). The proportion of 
positive transition was more frequent among those with FLG variants and allergic 
sensitization as compared to those without both risk factors across all transition periods. 
For instance, in the presence of both FLG variants and allergic sensitization, 5/16 
(31.3%) of those without asthma at age 4 years developed asthma at age 10 years; 
whereas, only 23/532 (4.3%) of those without both risk factors developed asthma at 10 
years. Furthermore, the presence of both risk factors influenced the persistence of asthma 
(table 3.2). For example, 18/21 (85.7%) of participants with both risk factors who had 
asthma at ages 10 years continued to have asthma at 18 years, as compared to 25/44 
(56.8%) among those without the two risk factors. Similarly, the presence of both FLG 
variants and preceding eczema influenced the positive transition and persistence of 
asthma. 
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3.4.3 FLG VARIANTS AND RHINITIS 
FLG variants were associated with increased risk for rhinitis from age 1-or-2 to 
18 years in the total study sample of repeated measurements (RR = 1.37, 95% CI: 1.16 – 
1.63; figure 3.3). In both the presence (RR = 1.57, 95% CI: 1.23 – 2.00) and absence (RR 
= 1.28, 95% CI: 1.04 – 1.57) of eczema, the association between FLG variants and 
rhinitis was statistically significant. However, we observed a statistically significant 
association between FLG variants and rhinitis only in the presence of allergic 
sensitization (RR = 1.34, 95% CI: 1.17 – 1.53), and not in its absence (RR = 1.13, 95% 
CI: 0.82 – 1.55; figure 3.3).  
To test if the observed heterogeneous effects across the levels of the potential 
effect modifiers are statistically different, we tested multiplicative statistical interactions 
in concurrent models. There was no evidence for an interactive effect neither between 
FLG variants and eczema (interaction effect RR = 1.15, 95% CI: 0.83 – 1.60, Pinteraction = 
0.409; figure 3.3) nor between FLG variants and allergic sensitization (interaction effect 
RR = 1.07, 95% CI: 0.76 – 1.51, Pinteraction = 0.698; figure 3.3) on the risk for rhinitis. 
Concordant with results of concurrent models, the delayed effect models did not show 
any interactions between FLG variants and preceding allergic sensitization or eczema on 
the risk of subsequent rhinitis (figure 3.4). 
 
3.4.4 SEX DIFFERENCES AND TIME TRENDS 
Separate analyses for each sex were performed and the results for boys and girls 
were similar (data not shown) and in agreement with the results of analyzing both sexes 
together in the repeated measurement (GEE) analysis. Furthermore, at each follow-up we 
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analyzed boys and girls separately to determine whether the effects differ across both 
time and sex. The obtained results indicated that neither age of exam nor sex influenced 
our results. 
 
3.5 DISCUSSION 
The objective of this study was to determine whether eczema and/or allergic 
sensitization status act as effect modifiers for the association of FLG variants with asthma 
and rhinitis. In this study, FLG variants increased the risk of asthma and rhinitis during 
the first 18 years of life in the total study sample. In concurrent effect models, interaction 
between FLG variants and allergic sensitization resulted in a combined effect that 
increased the risk of coexisting asthma by 3.63-fold. Delayed effect models, which take 
the time order of risk factors and disease occurrences into account, supported the findings 
of the concurrent effect models regarding allergic sensitization and FLG variants. In 
addition, the delayed effect models showed that FLG variants interact with preceding 
eczema status on the development of subsequent asthma, indicating that both allergic 
sensitization and eczema act as effect modifiers for the association between FLG variants 
and asthma. In contrast, neither eczema nor allergic sensitization modified the association 
of FLG variants with rhinitis in a statistically significant manner.  
The association between FLG variants and asthma among those with eczema was 
first reported by Palmer et al. [53]. Subsequently, several studies have replicated this 
association and added a possible association between FLG variants and rhinitis [59, 66]. 
Results of our study further support the general agreement that FLG variants are 
associated with asthma in the presence of eczema. We further demonstrated that both 
37 
preceding allergic sensitization and eczema modified the association between FLG 
variant and asthma through multiplicative interaction (figure 3.2). These findings indicate 
that FLG variants need eczema or allergic sensitization to execute their adverse effects on 
asthma. The finding of an interaction between FLG variants and allergic sensitization in 
this study improves our understanding of the possible link between genetics of the 
epidermal barrier (i.e., FLG variants) and a respiratory disorder (i.e., asthma). Such an 
observation further supports the hypothesis that cutaneous sensitization priming, 
facilitated by FLG variants, may migrate to the airways and cause local and systematic 
inflammation [98]. Although prior studies have widely suggested such a pathway, the 
majority of previous investigations did not take the status of allergic sensitization into 
account. An exception is the study by Marenholz et al., which showed an interaction 
between FLG variants and food sensitization on the risk of asthma in children with 
eczema [97], however, their analytical sample was restricted to children with eczema. 
In the delayed effect models we used the prevalence of asthma as the outcome, 
which does not distinguish between new occurrences and persistence of asthma. 
Therefore, in additional descriptive analysis, we demonstrated that the presence of both 
FLG variants and preceding allergic sensitization or preceding eczema influenced the 
new occurrences (positive transition) and persistence of asthma. Hence, our data suggest 
that the presence of both risk factors (‘FLG variants and preceding allergic sensitization’ 
or ‘FLG variants and preceding eczema’) plays an important role in the development and 
persistence of asthma. 
Attempts using the composite of ‘atopic asthma’ phenotype were conducted to 
investigate whether allergic sensitization is the link between FLG variants and asthma. 
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Inconsistent results for the association of FLG variants with ‘atopic asthma’ have been 
reported [62, 64, 99, 100]. These inconsistencies could be attributed to the use of the 
composite ‘atopic asthma’ phenotype, which does not clearly define the reference (no 
risk) group. By taking this approach investigators tend to group ‘non-atopic asthmatics’ 
and ‘atopics without asthma’ participants together in the reference group. Therefore, 
when assessing the association of FLG variants with ‘atopic asthma’ one should be aware 
that the reference group could include atopic participants, which could result in distorting 
assessments. The advantage of our approach, using two separate risk factors, over the 
composite ‘atopic asthma’ phenotyping, is that we were able to estimate the additional 
effect due to interaction (FLG variants × allergic sensitization) that is above and beyond 
their independent effects. Hence, allowing us to determine whether the combined effect 
of both risk factors is more than just the multiplication of their independent effects. 
There is conflicting evidence in the literature as to whether the association 
between FLG variants and rhinitis is modulated by eczema status. The majority of 
previous studies found a stronger association between FLG variants and rhinitis in the 
presence of coexisting eczema when compared to their association in the absence of 
concurrent eczema [62, 63, 65, 66, 101]. Another investigation reported an association 
between FLG variants and ‘persistent allergic rhinitis’ phenotype [99]. Controversially, 
however, a significant association has also been reported between FLG variants and the 
composite ‘allergic rhinitis’ phenotype adjusted for eczema status [64]. Our analyses did 
not reveal interaction between eczema (Pinteraction = 0.409) or allergic sensitization 
(Pinteraction = 0.698) with FLG variants on the risk of rhinitis in the repeated measurement 
analysis. Our results of an interactive effect between FLG variants and allergic 
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sensitization on the risk of asthma and the lack of such interaction on the risk of rhinitis 
suggest that the pathway through which FLG variants predispose to asthma and rhinitis 
may be different. For instance, the expression of filaggrin protein was not detected in the 
human bronchial epithelium; however, it has been shown that filaggrin is expressed in the 
nasal vestibule [64, 94]. That said, the extent to which filaggrin expression in the nasal 
vestibular lining influence the development of rhinitis is yet to be investigated by future 
studies. 
Major strengths of our prospective, 18-year study are the repeated phenotyping, 
objective assessments of allergic sensitization status, and the low loss to follow-up 
(ranged from 5% to 17%). Moreover, the majority (80%) of the study participants were 
genotyped for FLG variants common among populations of European ancestry [57]. We 
showed, previously, that the genotyped study participants did not differ from the total 
cohort with regard to multiple characteristics [79]. Hence, there is no indication of 
selection bias that could pose a threat to the validity of our study. Misclassification of 
eczema cases is minimal since a high proportion of subjects showed typical manifestation 
of eczema in the usual locations (antecubital or popliteal fossae, ankles, face or neck for 
97% at 1 year, 91% at 2 years, 75% at 4 years, 86% at 10 years and 76% at 18 years) 
[25].  
Potential limitations are the definition of asthma and rhinitis symptoms in early 
life. Our asthma conclusion at ages 10 and 18 years followed the ISAAC criteria [4], 
which was at that time not available for assessments at age 1, 2, and 4 years. Although 
slightly different methods were used to define asthma, in a previous report we have 
shown that the minor change in asthma definition over time did not influence the validity 
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of our asthma classification [37]. In addition, since it is difficult to differentiate between 
infectious and other forms of rhinitis in infancy, the elevated prevalence at 1-or-2 years 
might have been influenced by misclassifying ‘viral induced infectious rhinitis’ [33]. 
However, by applying repeated measurements analysis including assessments later in 
childhood and adolescence, we believe that the influence of the possible misclassification 
of rhinitis at 1-or-2 years on the overall results of the study is minimal, since similar 
results were obtained when we reran our analyses excluding the 1-or-2 year data. 
Moreover, since SPTs at age 1-or-2 years were performed on symptomatic children, we 
speculate that selection bias leading to underestimated RRs might have been induced. 
Although proportions of SPT positivity at ages 1-or-2 years (20.6%) and 4 years (19.6%; 
SPT performed irrespective of symptoms) were similar, RRs associating allergic 
sensitization at age 1-or-2 years with outcomes (i.e., eczema, asthma, and rhinitis) at the 
same age tended to be smaller than RRs relating allergic sensitization at age 4 years with 
outcomes at the same age (data not shown), since also the reference group had some 
symptoms. Hence, the estimated RRs at age 1-or-2 might be underestimated; however, 
the extent of the possible selection bias is minimal since our results did not noticeably 
change when we excluded the 1-or-2 years follow-up data from the analyses. Such 
observations further demonstrate the robustness of the GEE method in providing 
population averaged estimates (RRs) while accounting for the within-subject correlations 
of repeated measurements. The use of a slightly relaxed statistical significance threshold 
(PInteraction < 0.1) for detecting interaction-effects is further supported by the fact that 
majority of epidemiologic studies lack sufficient power to detect higher order-terms 
[102]. 
41 
In conclusion, our results indicate that allergic sensitization and eczema status are 
effect modifiers of the association between FLG variants and asthma. The combined 
effects of ‘preceding allergic sensitization and FLG variants’ and ‘preceding eczema and 
FLG variants’ increased the risk of subsequent asthma by 4.93-fold and 3.33-fold, 
respectively, during the first 18 years of life. These findings suggest that FLG variants 
need allergic sensitization or eczema to execute its adverse effects on asthma. In contrast, 
neither eczema nor allergic sensitization status statistically significantly modulated the 
association between FLG variants and rhinitis. Hence, results of our study suggest that 
the mechanisms and pathways through which FLG variants, representing impaired 
epidermal barrier, predispose to increased risk of asthma and rhinitis may be different. 
Future studies confirming our reported observations and exploring the differential 
etiological pathways underlying the development of asthma and rhinitis are needed to 
better identify and stratify those who share similar risk characteristics. 
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Figure 3.1. Concurrent association of FLG variants with asthma in total study sample 
and sub-samples: longitudinal analysis covering 1-or-2 to 18 years of age. The prevalence 
of asthma among those with filaggrin loss-of-function (FLG LOF) variants and those 
with wild-type genotype (FLG WT) is shown. RR: Risk ratio; 95% CI: 95% confidence 
interval; k= number of repeated measurements. 
 
 
43 
 
Figure. 3.2. a) Delayed effect models exploring the individual and combined effects of FLG variants and 
preceding allergic sensitization status on asthma development. Independent effects of FLG variants (SPT - 
& FLG LOF), positive SPT (SPT + & FLG WT), and their combined effect (SPT + & FLG LOF) in the 
development of asthma are shown for different ages. We modeled the effect of preceding SPT results on 
later asthma. b) Delayed effect models exploring the individual and combined effects of FLG variants and 
preceding eczema status on asthma development. Independent effects of FLG variants (Eczema - & FLG 
LOF), eczema (Eczema + & FLG WT), and their combined effect (Eczema + & FLG LOF) in the 
development of asthma are shown for different ages. We modeled the effect of preceding eczema results on 
later asthma. SPT +: positive SPT, SPT -: negative SPT; Eczema +: positive eczema diagnosis, Eczema -: 
negative eczema diagnosis; FLG LOF: filaggrin loss-of-function; FLG WT: filaggrin wild-type genotype; n 
= number of children; k= number of repeated measurements. The asterisk (*) and the double dagger (‡) 
indicate that the interaction effect (a: SPT × FLG; b: Eczema × FLG) is possibly statistically significantly 
different from the null value of 1 (*: PInteraction < 0.1; ‡: PInteraction < 0.05); suggesting interaction on 
multiplicative scale. The dagger (†) indicates that the risk estimate (RR) of the given column is statistically 
significantly (P < 0.05) different from the column without both risk factors (a: SPT - & FLG WT; b: 
Eczema & FLG WT). The presence of both an asterisk (*) or double dagger (‡) and dagger (†) signifies 
that the combined effect of the two risk factors is above and beyond their individuals effects. 
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Figure 3.3. Concurrent association of FLG variants with rhinitis in total study sample 
and sub-samples: longitudinal analysis covering 1-or-2 to 18 years of age. The prevalence 
of rhinitis among those with filaggrin loss-of-function (FLG LOF) variants and those 
with wild-type genotype (FLG WT) is shown. RR: Risk ratio; 95% CI: 95% confidence 
interval; k= number of repeated measurements. 
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Figure 3.4. a) Delayed effect models exploring the individual and combined effects of FLG variants and 
preceding allergic sensitization status on rhinitis development. Independent effects of FLG variants (SPT - 
& FLG LOF), positive SPT (SPT + & FLG WT), and their combined effect (SPT + & FLG LOF) in the 
development of rhinitis are shown for different ages. We modeled the effect of preceding SPT results on 
later rhinitis. b) Delayed effect models exploring the individual and combined effects of FLG variants and 
preceding eczema status on rhinitis development. Independent effects of FLG variants (Eczema - & FLG 
LOF), eczema (Eczema + & FLG WT), and their combined effect (Eczema + & FLG LOF) in the 
development of rhinitis are shown for different ages. We modeled the effect of preceding eczema results on 
later rhinitis. SPT +: positive SPT, SPT -: negative SPT; Eczema +: positive eczema diagnosis, Eczema -: 
negative eczema diagnosis; FLG LOF: filaggrin loss-of-function; FLG WT: filaggrin wild-type genotype; n 
= number of children; k= number of repeated measurements. The dagger (†) indicates that the risk estimate 
(RR) of the given column is statistically significantly (P < 0.05) different from the column without both 
risk factors (a: SPT - & FLG WT; b: Eczema & FLG WT). 
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Table 3.1. Characteristics of study population 
Attributes % (n/total) 
Sex  
   Male 51.2 (786/1536) 
  
Eczema at  
   1-or-2 years 14.2 (196/1377) 
   4 years 11.9 (145/1214) 
   10 years 13.7 (186/1359) 
   18 years 12.3 (161/1307) 
  
Asthma at  
   1-or-2 years 14.3 (197/1377) 
   4 years 14.9 (181/1214) 
   10 years 14.7 (201/1368) 
   18 years 17.7 (231/1305) 
  
Rhinitis at  
   1-or-2 years 15.8 (217/1377) 
   4 years 5.6 (65/1214) 
   10 years 22.6 (308/1362) 
   18 years 35.8 (468/1309) 
  
FLG variants*  
   R501X 4.1 (47/1161) 
   2282del4 4.6 (54/1168) 
   S3247X 1.6 (18/1165) 
   Combined 10.3 (118/1150) 
  
Allergic sensitization† at  
   1-or-2 years 20.6 (106/515) 
   4 years 19.6 (192/982) 
   10 years 26.9 (279/1036) 
   18 years 41.4 (353/853) 
*Analyses were conducted using the combined carrier frequency of 10.3%. 
† Presence of allergic sensitization was defined by having on or more positive skin prick 
test result at the respective assessment. 
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Table 3.2. Prevalence, positive transition, and persistence of asthma stratified based on 
FLG variants and preceding allergic sensitization and eczema status: comparing 
proportions of those with both risk factors to those without the risk factors 
 Asthma % (n/total) 
Prevalence Age 4 years Age 10 years Age 18 years 
FLG WT & SPT – 18.4 (57/310) 7.9 (47/595) 10.3 (62/604) 
FLG LOF & SPT + 50.0 (9/18) 60.0 (18/30) 54.8 (23/42) 
p-value* 0.003 < 0.001 < 0.001 
    
FLG WT & Eczema – 11.9 (86/725) 11.2 (91/811) 16.0 (118/739) 
FLG LOF & Eczema + 52.0 (5/6) 51.5 (17/33) 51.3 (20/39) 
p-value* < 0.001 < 0.001 < 0.001 
    
Positive transition
† 
1-or-2 to 4 years 4 to 10 years 10 to 18 years 
FLG WT & SPT – 8.5 (19/223) 4.3 (23/532) 6.7 (37/550) 
FLG LOF & SPT + 50.0 (6/12) 31.3 (5/16) 23.8 (5/21) 
p-value* < 0.001 < 0.001 0.014 
    
FLG WT & Eczema – 8.5 (53/635) 7.0 (44/632) 9.3 (59/639) 
FLG LOF & Eczema + 42.1 (8/19)) 29.4 (5/17) 14.3 (3/21) 
p-value* < 0.001 0.006 0.437 
    
Persistence
‡ 
1-or-2 to 4 years 4 to 10 years 10 to 18 years 
FLG WT & SPT – 43.7 (38/87) 38.7 (24/62) 56.8 (25/44) 
FLG LOF & SPT + 50.0 (3/6) 92.9 (13/14) 85.7 (18/21) 
p-value* 0.542 < 0.001 0.026 
    
FLG WT & Eczema – 36.7 (33/90) 44.7 (38/85) 68.3 (56/82) 
FLG LOF & Eczema + 83.3 (5/6) 80.0 (12/15) 94.4 (17/18) 
p-value* 0.031 0.023 0.037 
FLG LOF: filaggrin loss-of-function; FLG WT: filaggrin wild-type genotype; SPT -: negative skin prick 
test result; SPT +: positive skin prick test result. 
* 
p-values comparing the proportions across the two exposure groups were derived from fisher’s exact test. 
† Positive transition refers to the change in disease status from asthma-free to asthma in two consecutive 
assessments. 
‡ Persistence refers to the proportion of individuals who had asthma at two consecutive assessments 
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CHAPTER 4 
RESULTS II 
 
MANUSCRIPT # 2: ALLERGIC SENSITIZATION AND FILAGGRIN VARIANTS PREDISPOSE TO 
THE COMORBIDITY OF ECZEMA, ASTHMA, AND RHINITIS: RESULTS FROM THE ISLE OF 
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4.1 ABSTRACT 
Background: Allergic sensitization and filaggrin gene (FLG) variants are important risk 
factors for allergic disorders; however, knowledge on their individual and interactive 
effects on the coexistence of eczema, asthma, and rhinitis is lacking.  
Objective: This study aimed at investigating the single and combined effects of allergic 
sensitization and FLG variants on the development of single and multiple allergic 
disorders.  
Methods: The Isle of Wight Birth Cohort (n = 1,456) has been examined at 1, 2, 4, 10, 
and 18 years of age. Repeated measurements of eczema, asthma, rhinitis, and skin prick 
tests were available for all follow-ups. FLG variants were genotyped in 1,150 
participants. Associations of allergic sensitization and FLG variants with single and 
multiple allergic disorders were tested in log-binomial regression analysis. 
Results: The prevalence of eczema-, asthma-, and rhinitis-only ranged from 5.6% to 
8.5%, 4.9% to 10.2%, and 2.5% to 20.4%, respectively, during the first 18 years of life. 
The coexistence of allergic disorders is common, with approximately 2% of the 
population reporting the comorbidity of “eczema, asthma, and rhinitis” during the study 
period. In repeated measurement analyses, allergic sensitization and FLG variants, when 
analyzed separately, were associated with having single and multiple allergic disorders. 
Of particular significance, their combined effect increased the risk of “eczema and 
asthma” (RR = 13.67, 95% CI: 7.35 – 25.42), “asthma and rhinitis” (RR = 7.46, 95% CI: 
5.07 – 10.98), and “eczema, asthma, and rhinitis” (RR = 23.44, 95% CI: 12.27 – 44.78). 
Conclusions and Clinical Relevance: The coexistence of allergic disorders is frequent 
and allergic sensitization and FLG variants jointly increased risk of allergic 
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comorbidities, which may represent more severe and complex clinical phenotypes. The 
interactive effect and the elevated proportion of allergic comorbidities associated with 
allergic sensitization and FLG variants emphasize their joint importance in the 
pathogenesis of allergic disorders. 
 
4.2 INTRODUCTION 
Allergic disorders, including eczema, asthma, and rhinitis, pose social and 
economic burden on individuals, families, and societies [1, 2]. Worldwide, the lifetime 
prevalence of eczema symptoms (e.g., itchy rash) is estimated to be 15% to 30% among 
children and 2% to 10% among adults [19]. Similarly, the prevalence of asthma (up to 
25%) and rhinitis (up to 30%) is high [16, 29, 32]. Natural history investigations have 
demonstrated close and complex relationships between these allergic disorders [25, 33, 
48, 103-105]. However, mechanisms and pathways underlying their development is an 
area of ongoing scientific dispute. 
The “allergic march” concept suggests that allergic disorders develop in a 
sequential pattern, starting with eczema in early infancy and later in childhood 
developing asthma and rhinitis [106]. However, supporting replicable evidence and 
consensus is far from complete [42, 107, 108]. An opposing concept is the “coexistence” 
of allergic morbidities [42, 45, 109]. A report based on the German Multicenter Allergy 
Study showed that single occurrence of eczema early in life does not result in an allergic 
march, but the coexistence of eczema and wheezing predicted asthma [45]. Results from 
the BAMSE birth cohort showed that the comorbidity of allergic disorders is frequent 
during the first 12 years of life [109]. Such observations speak in favor of coexistence of 
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allergic morbidities instead of a progressive development. The interrelationship between 
these conditions and the risk factors that predispose individuals to develop multiple 
allergic disorders is an open field for research. 
Interplay between genetic, environmental, and immunological factors is 
considered to contribute to the pathogenesis of allergic disorders [110]. Allergic 
sensitization, defined as the susceptibility to produce immunoglobulin E (IgE) antibodies 
in response to antigens, is widely-considered as a common thread linking various 
manifestations of allergic disorders [49, 96]. Likewise, loss-of-function variants in the 
filaggrin gene (FLG) resulting in an impaired epidermal barrier have rapidly emerged as 
common risk factor for the development of allergic disorders [60]. However, there is a 
gap in understanding of the respective contribution of FLG variants and allergic 
sensitization on the development of allergic comorbidities. Moreover, the joint role of 
FLG variants and allergic sensitization on the coexistence of eczema, asthma, and rhinitis 
has not been previously investigated. Using data from the Isle of Wight (IOW) birth 
cohort, we aimed at determining the single and combined effects of FLG variants and 
allergic sensitization on the development of single and multiple (coexisting) allergic 
disorders.  
 
4.3 MATERIALS AND METHODS 
4.3.1 STUDY DESIGN AND PARTICIPANTS 
An unselected whole population birth cohort (n = 1,536) was recruited in 1989 on 
the Isle of Wight, UK, to prospectively study the natural history of allergic conditions. 
After exclusion of adoptions, perinatal deaths, and refusal for follow-up, written informed 
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consent was obtained from parents to enroll 1,456 (95%) newborns, with follow-up 
assessments conducted at 1, 2, 4, 10, and 18 years of age. Ethics approvals were obtained 
from the Isle of Wight Local Research Ethics Committee (now named the National 
Research Ethics Service, NRES Committee South Central – Southampton B) at 
recruitment and for the subsequent follow-ups (06/Q1701/34).  
 
4.3.2 PHENOTYPES 
In all assessments of the IOW birth cohort, eczema was defined as chronic or 
chronically relapsing, itchy dermatitis lasting more than 6 weeks with characteristic 
morphology and distribution [83], following Hanifin and Rajka criteria [84]. For asthma, 
at the 1, 2, and 4-year follow-ups, the medical investigator determined the presence of 
asthma based on wheeze over the last 12 months and treatment given for asthma or 
asthma related symptoms. At the 10 and 18 year follow-ups, asthma was defined as 
having “ever had asthma” and either “wheezing or whistling in the chest in the last 12 
months” or “current treatment for asthma”, following the International Study of Asthma 
and Allergies in Childhood (ISAAC) criteria [4]. Rhinitis was defined by a problem with 
sneezing, or a runny or a blocked nose without a cold or the flu in the last 12 months 
[33]. Since the 1-year and 2-year follow-up data were collected in a relatively small time 
window, we combined them for analytic purposes (reported as 1-or-2 years). 
To determine allergic sensitization, skin prick tests (SPTs) at ages 1 and 2 years 
were performed on children with any symptoms of eczema, asthma, or rhinitis. Parallel to 
the disorders, we combined the SPTs at ages 1 and 2 years (reported as 1-or-2 years). At 
4, 10, and 18 years, regardless of symptoms, SPTs were performed on most children 
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attending the research center using 14 common food and aeroallergens (ALK-Albello, 
Horsholm, Denmark) [111]. Allergic sensitization was defined by having a positive SPT 
to at least one test with mean wheal diameter of 3 mm greater than the negative control. 
Since allergic sensitization is a dynamic phenotype, we used the concurrent status and 
thus allowed the risk to change over time.  
 
4.3.3 FLG GENOTYPING 
Blood and/or saliva samples were collected at ages 10 and/or 18 years from which 
genomic DNA was isolated. DNA samples were interrogated using GoldenGate 
Genotyping Assays on the BeadXpressVeracode platform (Illumina, Inc, SanDiego, CA) 
per Illumina’s protocol. Individuals carrying the minor allele for at least one of the FLG 
variants R501X, 2282del4, or S3247X were classified as having filaggrin 
haploinsufficiency. Detailed information on genotyping is provided by Ziyab et al [79]. 
 
4.3.4 STATISTICAL ANALYSIS 
The 12-month period prevalence of eczema, asthma, rhinitis, and their 
comorbidities combinations was determined for each follow-up. Combinations of three 
disorders resulted in eight non-overlapping comorbidities groups (Table 4.1). To estimate 
the single and combined effects of the risk factors, FLG variants and repeated measures 
of allergic sensitization, on allergic disorders, generalized estimating equations (GEE) 
were used when estimating the covariance matrix to account for correlated observations 
and the within-child effect of the repeated measurements [88]. Risk ratios (RR) and their 
95% confidence intervals (95% CIs) were estimated by applying log-binomial regression 
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models using the GENMOD procedure in SAS 9.3 (SAS, Gary, NC, USA). The “no 
allergic disorder” category formed the reference category. The main effects of FLG 
variants and allergic sensitization on the risk for single allergic disorders and 
comorbidities were estimated separately (single risk factor models). In a full model, the 
two main plus their interaction effect (FLG variants × allergic sensitization) were 
estimated. We repeated the aforementioned analysis while excluding the 1-or-2 years 
follow-up data from the GEE analysis to estimate whether possible misclassifications of 
phenotypes at early life biased our results. In the case of a possibly statistically 
significant interaction (Pinteraction < 0.1), the combined effect was estimated as follows: RR 
= exp[(β1 × allergic sensitization) + (β2 × FLG variants) + (β3 × [allergic sensitization × 
FLG variants])]. The term ‘combined effect’ was used to describe the joint impact of two 
individual risk factors plus their interaction on the occurrence of the outcome. In all GEE 
models, sex and age at follow-up were included as potential confounders. To evaluate 
statistical significance of main effects of covariates (not interaction terms), a P value ≤ 
0.05 was used as indicator of statistical significance. 
Population attributable fractions (PAFs), defined as the proportion of disease that 
can be related to a specific risk factor(s) [89], were estimated using the following 
formula: PAF = pc × [(RR – 1)/RR], where pc is the proportion of diseased-individuals 
that are exposed [89, 90]. This approach yields valid PAF estimates in the presence of 
confounding and/or effect modification, only when using adjusted RRs [89, 90]. In case 
of statistically significant interactions between allergic sensitization and FLG variants, 
the RRs for the combined effect were used to estimate PAFs associated with both risk 
factors. If no interaction was detected, adjusted RRs were used to estimate separate PAFs 
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for each of the two risk factors and an overall PAF was obtained using the following 
formula: PAFoverall = 1 – [(1 – PAFallergic sensitization) × (1 – PAFFLG variants)] [89]. 
 
4.4 RESULTS 
A total of 1,377, 1,210, 1,345, and 1,298 children, out of 1,456, had available 
information on eczema, asthma, and rhinitis diagnosis at ages 1-or-2, 4, 10, and 18 years, 
respectively (Table 4.1). SPT results were available for 515 (age 1-or-2: only children 
with any symptoms), 982, 1,036, and 853 children at ages 1-or-2, 4, 10, and 18 years, 
respectively. The proportion of positive SPTs increased from 20.6% to 41.4% between 
ages 1-or-2 and 18 years. Although SPT at age 1-or-2 was performed only on 
symptomatic children, the proportion of sensitized children at ages 1-or-2 and 4 years 
were similar (20.6% vs. 19.6%). The combined proportion of carriers (heterozygous) of 
FLG variants R501X, 2282del4 and S3247X was 10.3% (118/1150; Table 4.1).  
 
4.4.1 PREVALENCE OF ALLERGIC DISORDERS 
The period prevalence of “eczema only” was between 7.9% and 8.5% during the 
first 10 years of life and decreased to 5.6% at 18 years of age (Table 4.1). “Asthma only” 
was most prevalent (10.2%) at 4 years. The period prevalence of “rhinitis only”, despite 
the drop at age 4, demonstrated an increasing trend over time by reaching 20.4% at 18 
years of age. The comorbidity of “eczema and asthma” and “eczema and rhinitis” ranged 
from 0.6% to 2.4% and 0.6% to 3.6%, respectively, between 1-or-2 and 18 years. Having 
“asthma and rhinitis” was most common (9.0%) at age 18 years. A coexistence of 
eczema, asthma, and rhinitis was found in approximately 2% over the study period. 
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4.4.2 ASSOCIATION ANALYSIS: SINGLE RISK FACTOR MODELS 
FLG variants showed increased risk of “eczema only” (RR = 1.37, P = 0.101) and 
“rhinitis only” (RR = 1.27, P = 0.064; Table 4.2) that was not statistically significance, 
during the first 18 years of life. However, FLG variants predisposed to increased risk of 
having “eczema + asthma” (RR = 2.41, P < 0.01), “asthma + rhinitis” (RR = 1.52, P < 
0.01), and a trend for increased risk of “eczema + rhinitis” (RR = 1.69, P = 0.077). 
Moreover, the risk of “eczema, asthma, and rhinitis” was 3.43 fold-higher among those 
with FLG haploinsufficiency than those with functional FLG gene. Accordingly, FLG 
variants showed stronger associations with allergic comorbidities than single disorders. 
Allergic sensitization, statistically significantly, increased the risk of “eczema-“, 
“asthma-“, and “rhinitis-only” by 1.70-, 2.50-, 2.76-fold over the study period (Table 
4.2). In addition, allergic sensitization predisposed to increased risk of having “eczema + 
asthma” (RR = 6.64, P < 0.01), “eczema + rhinitis” (RR = 3.48, P < 0.01), and “asthma + 
rhinitis” (RR = 4.71, P < 0.01). In particular, allergic sensitization was associated with an 
increased risk for the coexistence of “eczema, asthma, and rhinitis” (RR = 9.22, P < 
0.01).  
 
4.4.3 ASSOCIATION ANALYSIS: TWO RISK FACTORS MODELS 
Simultaneously adjusting for FLG variants and allergic sensitization plus their 
interaction effect allowed us to determine their individual and combined effects. In these 
adjusted models, FLG variants did not show any association with allergic disorders 
(Table 4.3). In contrast, allergic sensitization was significantly associated with all allergic 
disorders. FLG variants and allergic sensitization showed possible interactive effects for 
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three of the studied comorbidities. Combined effect of allergic sensitization and FLG 
variants increased the risk of “eczema and asthma” (RR = 13.67, P < 0.01), “asthma and 
rhinitis” (RR = 7.46, P < 0.01), “eczema, asthma, and rhinitis” (RR = 23.44, P < 0.01; 
Table 4.3). To estimate whether the possible misclassifications of rhinitis/asthma at age 
1-or-2 years influenced our results, we repeated the previous analyses while excluding 
data from the 1-or-2 years. Comparable results were obtained when we repeated our 
analysis by only including data from 4, 10, and 18 years follow-ups in the GEE analysis 
(data not shown).  
 
4.4.4 SEX DIFFERENCES 
To determine whether sex is a potential effect modifier, we ran separate models 
for boys and girls. The effects of FLG variants and allergic sensitization on the risk of 
having single and multiple morbidities were similar for boys and girls. For instance, FLG 
variants associated with 2.95-fold (95% CI: 1.35 – 6.42, P < 0.01) higher risk of having 
‘eczema + asthma + rhinitis’ among boys; whereas, a 3.97-fold (95% CI: 1.96 – 8.05, P < 
0.01) higher risk was observed among girls (Pinteraction for sex = 0.597; detailed data not 
shown). 
 
4.4.5 POPULATION ATTRIBUTABLE FRACTIONS (PAFS) 
PAFs related to FLG variants and allergic sensitizations were estimated for the 
different allergic disorders using adjusted RRs from Table 4.3. A larger fraction of 
allergic disorders in the population can be related to allergic sensitization than to FLG 
variants, when simultaneously adjusting for their effects (Table 4.4). Around 13.7% to 
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29.5% of single allergic disorders might be related to having both allergic sensitization 
and FLG variants. High PAFs for having “eczema, asthma, and rhinitis” (49%), “eczema 
+ asthma” (33.7%), and “asthma + rhinitis” (21.2) were related to the combined effect of 
both allergic sensitization and FLG variants.  
 
4.5 DISCUSSION 
In this well-characterized longitudinal study, allergic comorbidities were 
prevalent at all ages. For the first time, we assessed the single and combined effects of 
FLG variants and allergic sensitization on the development of single allergic disorders 
and comorbidities. FLG variants, when adjusting for the effect of allergic sensitization, 
did not show any association with allergic disorders. Against that, allergic sensitization, 
adjusting for the effect of FLG variants, increased the risk of all allergic disorders. 
Substantial combined effects of both factors were detected for allergic comorbidities. For 
instance, a 23-fold increased risk for having “eczema, asthma, and rhinitis” 
(approximately 2% of the cohort) was associated with the presence of both FLG variants 
and allergic sensitization. 
Investigating and understanding the role of deviated immune responses, i.e. 
allergic sensitization, in the atopic diathesis have dominated the research field. However, 
the discovery of FLG variants and their pronounced role in the development of allergic 
disorders, eczema in particular, has caused a shift in the research paradigm toward 
understanding the contribution of dysfunctional skin barrier. FLG variants are considered 
to result in a compromised epidermal barrier that is characterized by increased 
penetration of allergens and microbes and elevated transepidermal water loss [60]. In 
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eczema, the role of FLG variants is well established; however, since FLG is not 
expressed in the respiratory epithelia its contribution to the development of allergic 
disorders of the airways is not clear [56, 60]. A suggested pathway is that cutaneous 
sensitization, facilitated by FLG variants, could lead to local and systematic inflammation 
at distant organs (i.e., lung and nasal tissues) [56]. Also the contrary is of importance, 
since it has been shown that inflammatory Th2 cytokines can also alter the integrity of 
the skin barrier, even in the absence of genetic variants that disrupt its integrity and 
function [112]. Hence, the two competing views: “inside-outside” which suggests that 
immunologic abnormality is the initiating and triggering step in the pathogenesis of 
allergic disorders and the “outside-inside” which posits that a defective epidermal barrier 
is the driver with epiphenomenal immunological sequelae, seem to be plausible and to 
some extent interdependent [77]. Therefore, simultaneously considering the contribution 
of genetic predisposition toward a defective skin barrier (i.e., FLG variants) and the 
propensity for immune dysregulation (i.e., allergic sensitization) could provide new and 
improved insights into the etiopathogenesis of allergic disorders. 
Previous studies showed that FLG variants increased the risk of eczema and 
predisposed to higher risk of asthma and rhinitis only in the presence of coexisting 
eczema [59, 66]. Hence, suggesting that FLG variants increase the risk of allergic 
comorbidities, such as ‘asthma plus eczema’ and ‘rhinitis plus eczema’. Our results 
further support and add to the previously reported findings. However, we showed that 
FLG variants did not pose any increased risk of single and multiple allergic disorders 
while controlling for the effect of allergic sensitization. But, significant interactive effects 
of both risk factors were associated with increased risk of allergic comorbidities. 
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Although previous investigations inconsistently showed that FLG variants increased the 
risk of allergic sensitization [65, 66, 99], we did only observe a weak association between 
FLG variants and allergic sensitization in this cohort [79]. The possibility of an 
association between FLG variants and allergic sensitization cannot be totally excluded; 
however, since only around 15% of those with allergic sensitization carry FLG variants in 
our cohort, we speculate that any possible indirect effect of FLG variants on allergic 
diseases that goes through allergic sensitization to be minimal. Moreover, the possibility 
of non-independence between the two factors, also known as gene-environment 
correlation, might bias the interactive effects [113]. Due to the weak non-significant 
association between FLG variants and allergic sensitization in our cohort, we have little 
concern that the unlikely non-independence of the two factors might bias the observed 
interactive effects. In support of our analytical model, we clearly demonstrated in a 
previous report that FLG variants posed no increased risk of eczema in the absences of 
allergic sensitization, whereas, allergic sensitization increased the risk of eczema 
independent of FLG variants and the combined effect of both factors led to elevated risk 
above and beyond their individual effects [79]. Similarly, Wang et al. showed that the 
association between FLG variants and eczema was limited to a subset of children with 
IgE levels ≥ 100 kU/L [114]. Hence, we suggest considering the combined effect of both 
risk factors rather than taking the cause-effect approach could lead to a better risk 
assessment. 
Our estimated PAFs suggested that approximately 21% to 49% of allergic 
comorbidities in the population may be attributed to the presence of both FLG variants 
and allergic sensitization. In agreement with results of this report, it has been shown that 
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a large proportion (38%) of allergic comorbidities can be explained by allergic 
sensitization alone [115]. Although, the contribution of FLG variants to the overall PAFs 
seems to be limited while controlling for the main effect of allergic sensitization, the 
PAFs associated with the combined effects of both risk factors (i.e., in the presence of 
possible interactive effects between FLG variants and allergic sensitization) is 
substantial. Our results suggest that FLG variants need allergic sensitization as a 
necessary component to execute its adverse effect. Therefore, early identification of those 
who are genetically predisposed to a dysfunctional skin barrier and who have increased 
allergic sensitization propensity may expedite the success of intervention/prevention 
efforts and measures. 
The etiologic approach taken so far by research in the field of FLG variants and 
allergic disorders has substantially improved our understanding of these multifactorial 
disorders. However, as suggested by Ballardini et al., allergic disorders should not be 
studied as single entities [109], rather investigating their coexistence could assess in 
identifying shared underlying risk factors. Hence, we considered all possible and non-
overlapping combinations of eczema, asthma, and rhinitis. Through this approach we 
were able to show that FLG variants increased the risk of allergic comorbidities rather 
than single disorders, suggesting its contribution towards a more severe and complex 
clinical phenotype. The effect of FLG variants when combined with the effect of allergic 
sensitization predisposed to even higher risk of allergic comorbidities. In contrast to 
investigating the coexistence of allergic disorders, evidence supporting the progression of 
events (i.e., allergic march) also exists [116, 117]. For instance, a valid assumption is that 
eczema predisposes to allergic sensitization, which in turn predicts asthma and rhinitis. 
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However, evidence supporting both pathways exists: (i) eczema precedes allergic 
sensitization and (ii) allergic sensitization precedes eczema [118, 119]. In the context of 
FLG variants, we have demonstrated, previously, that the combined effect of FLG 
variants and allergic sensitization predisposed to increased risk of subsequent eczema 
[79]. Also, we showed that the combination of FLG variants and eczema (FLG variants 
alone does not) increased the risk of subsequent allergic sensitization, which was limited 
to the first 10 years of life. Taken together, these observations suggest that multiple 
pathways could underlie the development of allergic disorders. Therefore, the 
development of allergic disorders is more complex and do not necessarily follow the 
atopic march paradigm. Although our approach does not take into account the sequence 
of the individual allergic manifestations, results of this report demonstrated that the co-
manifestation of allergic disorders is common and FLG variants and allergic sensitization 
are common risk factors. 
Major strengths of our study are the repeated phenotyping and the low attrition 
(ranging from 5% to 17%). FLG variants genotypes were available for the majority 
(80%) of the study population. Previously, we demonstrated that the genotyped sample 
did not differ from the total cohort with respect to multiple characteristics [79]. Although 
skin prick tests were performed at the different follow-ups to determine sensitization 
status, not measuring specific IgE is a limitation to our study. Moreover, since SPTs at 
ages 1 and 2 years were performed on symptomatic children, we speculate that selection 
bias leading to underestimated RRs might have been induced. Although proportions of 
SPT positivity at ages 1-or-2 years (20.6%) and 4 years (19.6%; SPT performed 
irrespective of symptoms) were similar, RRs associating allergic sensitization at age 1-or-
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2 years with outcomes (i.e., eczema, asthma, and rhinitis) at the same age tended to be 
smaller than RRs relating allergic sensitization at age 4 years with outcomes at the same 
age (data not shown), since also the reference group had some symptoms. Hence, the 
estimated RRs at age 1-or-2 might be biased; however, the extent of the possible 
selection bias is minimal since our results did not noticeably change when we excluded 
the 1-or-2 years follow-up data from the analyses. Such observations further demonstrate 
the robustness of the GEE method in providing population averaged estimates (RRs) 
while accounting for the within-subject correlations of repeated measurements. 
Misclassification of eczema cases is minimal since a high proportion of subjects showed 
typical manifestation of eczema in usual locations (antecubital or popliteal fossae, ankles, 
face or neck for 97% at 1 year, 91% at 2 years, 75% at 4 years, 86% at 10 years and 76% 
at 18 years) [25]. In addition, the prevalence of eczema in our cohort (13.7% at age 10 
years and 12.3% at age 18 years) is comparable to results from ISAAC studies conducted 
among children aged 13–14 years in the United Kingdom (UK) (14.7% phase one and 
10.6% phase three) and other studies conducted in the UK [5, 120, 121].Other, potential 
limitations are the definition of asthma and rhinitis symptoms in early life. Our asthma 
conclusion at ages 10 and 18 years followed the ISAAC criteria [4], which was at that 
time not available for assessments at ages 1, 2, and 4 years. Although slightly different 
methods were used to define asthma; however, in a previous report we demonstrated that 
the minor change in asthma definition did not influence the validity of our asthma 
classification [37]. In addition, since it is difficult to differentiate between infectious and 
other forms of rhinitis in infancy, the elevated prevalence at 1-or-2 years (6.5% vs. 2.5% 
at age 4 years) might have been influenced by misclassifying ‘viral induced infectious 
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rhinitis’ [33]. The influence of the possible misclassification of rhinitis at 1-or-2 years on 
the overall results of the study is minimal since similar results were obtained when we 
reran our analyses while excluding the 1-or-2 year data. 
In conclusion, comorbidities of eczema, asthma, and rhinitis are prevalent and 
both allergic sensitization and FLG variants are common risk factors that predispose to 
the comorbidity of allergic disorders. The combination of both risk factors was associated 
with elevated risk of coexisting allergic manifestations. Approximately 21% to 49% of 
the comorbidities in the population are related to both allergic sensitization and FLG 
variants. The coexistence of allergic disorders might reflect more severe clinical 
phenotypes that require more and longer medical care. However, investigations of 
comorbidities and their underlying etiological risk factors are limited. Therefore, 
additional etiological investigations regarding allergic comorbidities are recommended, 
as this will allow for a better phenotypic characterization. 
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Table 4.1. Characteristics of the Isle of Wight study population at different ages 
 Follow-up at age 
 1-or-2 years 4 years 10 years 18 years 
% (n) n = 1377 n = 1210 n = 1345 n = 1298 
Sex     
Male 50.8 (700) 51.1 (618) 50.7 (682) 49.6 (644) 
     
No allergic disorders 68.9 (949) 74.1 (897) 61.8 (832) 52.7 (684) 
Eczema only 8.5 (117) 7.9 (96) 8.0 (107) 5.6 (73) 
Asthma only 4.9 (68) 10.2 (123) 6.3 (84) 5.5 (71) 
Rhinitis only 6.5 (89) 2.5 (30) 13.4 (181) 20.4 (265) 
Eczema + asthma 1.9 (26) 2.4 (29) 1.0 (14) 0.6 (7) 
Eczema + rhinitis 1.8 (25) 0.6 (7) 2.4 (32) 3.6 (47) 
Asthma + rhinitis 5.5 (75) 1.3 (16) 4.7 (63) 9.0 (117) 
Eczema + asthma + rhinitis 2.0 (28) 1.0 (12) 2.4 (32) 2.6 (34) 
     
Allergic sensitization n = 515 n = 982 n = 1036 n = 853 
≥ 1 positive SPT 20.6 (106) 19.6 (192) 26.9 (279) 41.4 (353) 
     
FLG variants* n = 1150 
Yes 10.3 (118) 
SPT: Skin prick test 
* FLG variants were present in 118 participants of the 1150 who were genotyped. The prevalence of FLG variants changes based on 
the analytical sample. 
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Table 4.2. Single risk factor models: associations of FLG variants and allergic sensitization with allergic conditions: longitudinal 
analysis from age 1-or-2 to 18 years 
 Single risk factor model: FLG 
variants
*
 
 Single risk factor model: Allergic 
sensitization
*
 
 FLG variants genotype  Allergic sensitization 
 WT (k = 3831)
$ 
LOF (k = 442)
$
  SPT – (k = 2453)
$
 SPT + (k = 929)
$
 
No allergic disorders (Ref.), % (k) 64.2 (2459) 54.3 (240)  65.3 (1602) 29.7 (276) 
Eczema only, % (k) 7.6 (291) 8.8 (39)  9.5 (234) 9.8 (91) 
RR (95% CI) 1.00 1.37 (0.94 – 1.99)  1.00 1.70 (1.36 – 2.12)‡ 
Asthma only, % (k) 6.6 (253) 6.1 (27)  7.2 (177) 9.7 (90) 
RR (95% CI) 1.00 1.07 (0.71 – 1.61)  1.00 2.50 (1.99 – 3.14)‡ 
Rhinitis only, % (k) 11.2 (428) 12.4 (55)  10.0 (246) 20.8 (193) 
RR (95% CI) 1.00 1.27 (0.99 – 1.64)  1.00 2.76 (2.34 – 3.27)‡ 
Eczema + asthma, % (k) 1.4 (52) 2.9 (13)  1.1 (27) 4.1 (38) 
RR (95% CI) 1.00 2.41 (1.28 – 4.57)‡  1.00 6.64 (4.18 – 10.54)‡ 
Eczema + rhinitis, % (k) 2.0 (76) 2.7 (12)  2.1 (52) 4.2 (39) 
RR (95% CI) 1.00 1.69 (0.95 – 3.02)  1.00 3.48 (2.35 – 5.18)‡ 
Asthma + rhinitis, % (k) 5.4 (205) 6.8 (30)  3.7 (90) 15.1 (140) 
RR (95% CI) 1.00 1.52 (1.04 – 2.23)†  1.00 4.72 (3.76 – 5.94)‡ 
Eczema + asthma + rhinitis, % (k) 1.8 (67) 5.9 (26)  1.0 (25) 6.7 (62) 
RR (95% CI) 1.00 3.43 (2.02 – 5.83)‡  1.00 9.22 (5.63 – 15.12)‡ 
WT: Wild-type; LOF: Loss-of-function; SPT – : Negative skin prick test; SPT +: Positive skin prick test; Ref.: represent the common reference category; k: 
refers to the total number of repeated measurements. 
* In all GEE models sex and age at follow-up were included as potential confounders. 
$
 The presented numbers in parenthesis (k = ) refer to the number of repeated measurements. See Table 4.1 for more information on the number of individuals. 
† P-value < 0.05 
‡ P-value < 0.01 
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Table 4.3. Two risk factors model: associations of FLG variants and allergic sensitization with allergic conditions: longitudinal 
analysis from age 1-or-2 to 18 years 
 Two risk factors model: FLG variants and allergic sensitization*   
 FLG variants genotype Allergic sensitization RRInteraction 
(PInteraction)
#
 
Combined effect
† 
 WT (k = 2707)$ LOF (k = 328)$ SPT – (k = 2164)$ SPT + (k = 871)$  
No allergic disorders (Ref.), % (k) 56.9 (1540) 46.3 (152) 66.1 (1431) 30.0 (261)   
Eczema only, % (k) 9.3 (252) 10.1 (33) 9.2 (200) 9.8 (85) 0.98  
RR (95% CI) 1.00 1.11 (0.81 – 1.54) 1.00 1.74 (1.38 – 2.19)‡ (0.961)  
Asthma only, % (k) 7.6 (205) 6.4 (21) 6.7 (144) 9.4 (82) 1.05  
RR (95% CI) 1.00 0.99 (0.65 – 1.53) 1.00 2.65 (2.07 – 3.39)‡ (0.926)  
Rhinitis only, % (k) 13.3 (360) 14.6 (48) 10.4 (226) 20.9 (182) 0.85  
RR (95% CI) 1.00 1.21 (0.95 – 1.55) 1.00 2.68 (2.25 – 3.19)‡ (0.538)  
Eczema + asthma, % (k) 1.6 (44) 4.0 (13) 1.0 (22) 4.0 (35) 5.46  
RR (95% CI) 1.00 0.49 (0.08 – 3.03) 1.00 5.12 (2.95 – 8.90)‡ (0.016) 13.67 (7.35 – 25.42)
‡ 
Eczema + rhinitis, % (k) 2.5 (68) 3.4 (11) 2.1 (46) 3.8 (33) 1.48  
RR (95% CI) 1.00 1.52 (0.85 – 2.69) 1.00 3.19 (2.09 – 4.89)‡ (0.511)  
Asthma + rhinitis, % (k) 6.7 (182) 8.2 (27) 3.4 (73) 15.6 (136) 2.04  
RR (95% CI) 1.00 0.79 (0.34 – 1.89) 1.00 4.57 (3.52 – 5.93)‡ (0.070) 7.46 (5.07 – 10.98)
‡ 
Eczema + asthma + rhinitis, % (k) 2.1 (56) 7.0 (23) 1.0 (22) 6.5 (57) 3.59  
RR (95% CI) 1.00 1.02 (0.25 – 4.16) 1.00 6.43 (3.62 – 11.42)‡ (0.053) 23.44 (12.27 – 44.78)
‡ 
WT: Wild-type; LOF: Loss-of-function; SPT – : Negative skin prick test; SPT +: Positive skin prick test; Ref.: represent the common reference category; k: 
refers to the total number of repeated measurements; RRInteraction: Risk ratio associated with the interaction term. 
* In all GEE models sex and age at follow-up were included as potential confounders. 
# P-value < 0.1 was used to indicate presence of possible statistical interaction. If there was no evidence of interaction, the interaction term was removed from the 
regression model and only the main effects were modeled. 
$ The presented numbers in parenthesis (k = ) refer to the number of repeated measurements. See Table 4.1 for more information on the number of individuals. 
† Combined effect was estimated only in the presence of possibly statistically significant interaction term (FLG variants × allergic sensitization; PInteraction < 0.1). 
‡ P-value < 0.01. 
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Table 4.4. Population attributable fractions of different allergic conditions related to FLG 
variants and allergic sensitization 
 FLG variants Allergic sensitization Overall 
PAF
†
 (%)  PAF (%)
* 
PAF (%)
* 
Eczema only 1.2 12.7 13.7 
Asthma only n/a‡ 22.6 22.6¶ 
Rhinitis only 2.1 28.0 29.5 
Eczema + asthma n/a$ n/a$ 33.7 
Eczema + rhinitis 4.8 28.7 32.1 
Asthma + rhinitis n/a$ n/a$ 21.2 
Eczema + asthma + rhinitis n/a$ n/a$ 49.0 
PAF: population attributable fraction; n/a: not available 
* PAFs were estimated using adjusted risk ratios obtained from Table 4.3. 
† In the presence of statistically significant interaction, overall PAF were estimated using 
the RR for the combined effect obtained from Table 4.3. 
‡ PAF was not estimated due to RR < 1.00. 
$ PAF was not estimated due to the presence of possible statistical interaction (see Table 
4.3). 
¶ This value represents the PAF associated with allergic sensitization only since PAF 
associated with FLG variants was not estimable. 
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CHAPTER 5 
RESULTS III 
 
MANUSCRIPT # 3: DNA METHYLATION OF THE EPIDERMAL DIFFERENTIATION COMPLEX IN 
RELATION TO ECZEMA STATUS: AN EXPLORATORY STUDY3 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                           
3 A. H. Ziyab, W. Karmaus, J. W. Holloway, H. Zhang, S. E. Steck, S. Ewart, S. H. 
Arshad. To be submitted to Journal of European Academy of Dermatology and 
Venereology. 
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5.1 ABSTRACT 
Background: Genetic variants within genes located across the epidermal differentiation 
complex (EDC) genomic region have shown associations with eczema risk. However, 
knowledge on the role of epigenetic mechanisms (e.g., DNA methylation) within the 
EDC locus on eczema risk is lacking. 
Objective: To evaluate associations between DNA methylation of CpG sites across the 
EDC genomic region with eczema status. 
Methods: DNA methylation levels of 256 CpG sites spanning the EDC locus were 
measured using Illumina's 450K array in three semi-independent cohorts; a subsample of 
the Isle of Wight birth cohort (n = 367 participants aged 18 years, discovery cohort), 
replication cohort I (n = 146; parents of the F2 generation), and replication cohort II (n = 
94; F2 generation). Associations between eczema status and DNA methylation were first 
assessed in the discovery cohort using linear regression. Methylation sites showing an 
association with eczema in the discovery cohort at a false discovery rate p-value < 0.1 
were taken forward for replication.  
Results: Differential DNA methylation of CpG site cg12048339 (located within 
promoter of S100A6 gene) was associated with eczema specifically among female 
participants of all study cohorts; whereas, aberrant DNA methylation of cg10959711 
(located within promoter of S100A11 gene) associated with eczema among male 
participants in all study samples. 
Conclusion: This exploratory study demonstrated that DNA methylation of the EDC 
genomic region could be an important factor in the development of eczema in a sex-
specific manner. Future studies corroborating our findings are needed. 
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5.2 INTRODUCTION 
 The elevated life-time prevalence of eczema among children (up to 30%) and 
adults (up to 10%) makes eczema a global public-health burden [22]. Immunologic 
dysregulation and defective epidermal barrier are the main hallmarks of eczema [46]. In 
last decades, etiologic research have focused on immune-related factors, including 
genetics of immune system, in the pathogenesis of eczema; however, the discovery, in 
2006, of loss-of-function variants in the filaggrin gene (FLG) have caused a shift in the 
research paradigm towards understanding factors that regulate the formation and integrity 
of the epidermal barrier [53, 68]. Filaggrin haploinsufficiency, defined as partial or 
complete loss of filaggrin (filament-aggregating protein) protein, is associated with the 
development of an impaired epidermal barrier that is characterized by increased 
penetration of environmental substances and elevated transepidermal water loss [93]. As 
yet, FLG variants are the strongest and most replicated genetic risk factors for eczema 
development [59]. 
 The FLG gene is located within a dense cluster of genes encoding structural and 
regulatory proteins that are essential for keratinocyte differentiation, known as the 
epidermal differentiation complex (EDC) [76, 81, 82]. The EDC locus, spanning 2 Mb on 
human chromosomal region 1q21, harbors around 60 genes encoding loricrin and 
involucrin proteins and gene-family clusters encoding: (i) small proline-rich (SPRR) and 
late cornified envelope (LCE) proteins, (ii) calcium-binding proteins (S100A), and (iii) 
S100-fused type proteins (SFTP) [76, 81, 82]. Apart from FLG variants, a limited number 
of studies identified variants in other genes within the EDC that are associated with 
eczema. For instance, conflicting results as to whether polymorphisms in the hornerin 
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gene (HRNR), located 78 kb from FLG gene, are associated with eczema risk have been 
reported [122, 123]. Regarding SPRR3, Marenholz et al. showed that a 24-bp deletion in 
the gene was associated with eczema [124]. However, Stemmler et al. did not find 
evidence of association between eczema and other EDC genetic variants than FLG 
variants [125]. Both, genome-wide linkage and association studies have detected signals 
of linkage/association between eczema and the EDC genomic locus [122, 126-128]. 
Morar et al. showed that the genetic linkage of eczema to the EDC region (LOD score = 
3.57) was not totally diminished after accounting for FLG variants (LOD score = 2.03) 
[129]. Hence, this finding point towards the presence of other genetic variants within the 
EDC that influence eczema development. On the other hand, the limited success, apart 
from FLG variants, of associating EDC gene variants with eczema is not promising. 
Moreover, candidate-gene and genome-wide association studies have only explained a 
small proportion of the high heritability (up to 85%) and clustering of eczema within 
families [68, 69]. 
 Epigenetic mechanisms (e.g., DNA methylation) may offer a complementary 
explanation when considering the role of EDC on eczema. DNA methylation addresses 
heritable genetic regulatory elements that alter gene activity (e.g., expression) without 
changing the underlying nucleotide sequence of the DNA [130] have been speculated as 
plausible predisposing factors in the development of eczema and might as well account 
for the unexplained genetic effects [69]. Currently, there is a lack of knowledge on the 
role of epigenetic mechanisms, in particular DNA methylation, of the EDC genomic 
locus in relation to eczema risk. Therefore, a comprehensive DNA methylation profiling 
of the EDC genomic region could further add understanding for this genomic region in 
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development of eczema. To this end, in an EDC-wide screening this explorative study 
aimed to evaluate the association of DNA methylation across the EDC region with 
eczema status in participants of the Isle of Wight birth cohort (aged 18 years, F1 
generation). The analyses further test any significant findings identified in the screening 
(discovery) in two semi-independent samples (pregnant cohort participant, their partners, 
and their offspring, the F2 generation). 
 
5.3 MATERIALS AND METHODS 
5.3.1 PARTICIPANTS AND CHARACTERISTICS 
 The Isle of Wight birth (IOW) cohort, an unselected population-based study, was 
recruited between January 1989 and February 1990 in the Isle of Wight, UK, to study the 
natural history and etiology of allergic diseases. After exclusion of adoptions, perinatal 
deaths, and refusal for follow-up, 1,456 children (95%) were enrolled, with follow-up 
assessments conducted at 1, 2, 4, 10, and 18 years of age. Ethics approvals were obtained 
from the Isle of Wight Local Research Ethics Committee at recruitment and for the 
subsequent follow-ups (06/Q1701/34). Written informed consent was obtained from 
parents, participants, or both. In this analysis, the discovery cohort is based on a 
subsample (n = 367, aged 18 years) of the IOW cohort that was randomly selected for 
epigenetic study (Figure 5.1). We consider two cohorts to test the reproducibility of the 
screening. Replication cohort I (n = 146; parents of the F2 generation) includes 
participants of the IOW cohort (28.8% were part of the discovery cohort) plus new 
participants. Expecting mothers and their partners were assessed before delivery. 
Replication cohort II (n = 94; F2 generation) includes the F2 newborns of the IOW 
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cohort participants (Figure 5.1). Infants were followed-up at ages 3-, 6-, and 12-months. 
In all study samples, eczema was defined as chronic or chronically relapsing, itchy 
dermatitis lasting more than 6 weeks with characteristic morphology and distribution, 
following Hanifin and Rajka criteria [84]. 
 
5.3.2 DNA METHYLATION PROFILING 
For the discovery cohort, DNA was extracted from whole blood collected at age 
18 years using a standard salting out procedure [85], and bisulfite-treated for cytosine to 
thymine conversion using the EZ 96-DNA methylation kit (Zymo Research, CA, USA). 
Similarly, whole blood of replication cohort I participants’ and cord blood of replication 
cohort II participants’ were collected and DNA was extracted and bisulfite converted 
following the aforementioned standard procedures. In all samples, Genome-wide DNA 
methylation was assessed using the Illumina Infinium HumanMethylation450 BeadChip 
(Illumina, Inc., CA, USA), which interrogates > 484,000 CpG sites associated with 
approximately 24,000 genes. For the purpose of this report, we restricted our analysis to 
256 CpG sites that span the EDC genomic region (location on human chromosome 1: 
151958685 – 153628983). Arrays were processed using a standard protocol [86], with 
multiple identical control samples assigned to each bisulfite conversion batch to assess 
assay variability and samples randomly distributed on microarrays to control against 
batch effects [131]. The BeadChips were scanned using a BeadStation, and the 
methylation level calculated for each queried CpG locus (cytosine-guanine dinucleotides) 
using the Methylation Module of BeadStudio software. We used the DNA methylation 
profiles of our participants to predict their cell-type composition via a method proposed 
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by Houseman et al. [132] and validated by Koestler et al. [133]. This method identified 
CpG loci from our data which were within differentially methylated regions (DMRs) 
known to distinguish between white blood cell types, then utilized our Beta-values to 
predict the proportions of CD8+ T-cells, CD4+ T-cells, natural killer cells, B-cells, 
monocytes and granulocytes for each sample. 
 
5.3.3 STATISTICAL ANALYSIS 
After performing quality control measures on DNA methylation data, Beta-values 
presented as the proportion of methylated (M) over methylated (M) and unmethylated (U) 
sites (Beta-value = M/[c+M+U], with c being constant to prevent dividing by zero) were 
calculated for each CpG site [87]. Beta-values provide intuitive biological interpretation 
(i.e., % methylation); however, (i) being constrained between values of 0 (unmethylated) 
and 1 (completely methylated) and (ii) demonstrating high heteroscedasticity in the lower 
and upper ends of the methylation range has raised concerns on the validity of this 
measure when performing statistical analysis [91]. The conversion of Beta-values to M-
values (M-value = log2(Beta-value/[1 – Beta-value]) has been shown to overcome the 
limitations of beta-values [91]. Moreover, the use of M-values, when performing 
statistical analysis, demonstrated increased reliability in terms of detecting differentially 
methylated CpG sites; however, M-values cannot be directly interpreted [91, 92]. 
Therefore, following previous recommendation [91], we used M-values when performing 
the statistical analysis and reported the statistics at the scale of Beta-values. 
All statistical analyses were conducted using SAS® version 9.3 (SAS Institute, 
Cary, NC, USA). In the discovery cohort, linear regression was used to test the 
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association between DNA methylation (M-values) of all CpG sites spanning the EDC 
region with eczema status adjusting for sex and cell-type composition. To minimize 
false-positive findings identified in 256 models, CpG sites with a false discovery rate 
(FDR) adjusted p-value < 0.1 were selected and considered as potentially associated with 
eczema. The selected CpG sites, in the discovery cohort, were taken forward and tested 
for their possible association with eczema status in replication cohorts I and II. Then, the 
selected CpG sites were tested for association with eczema in males and females 
separately. 
 
5.4 RESULTS 
 The 12-month period prevalence of eczema was 12.6%, 15.6%, and 16.7% in the 
discovery cohort, replication cohort I, and replication cohort II, respectively (Table 5.1). 
The period prevalence of eczema was statistically significantly higher among women 
compared to men in the discovery cohort (15.2% vs. 7.4%, p-value = 0.034) and 
replication cohort I (21.1% vs. 5.9%, p-value = 0.017). In contrast, eczema was more 
common among infant boys (21.1%) in comparison with infant girls (11.8%) in 
replication cohort II. 
 Epigenome-wide DNA methylation profiling, covering more than 484,000 CpG 
sites across the genome, was performed in all three study samples. We restricted our 
analysis to 256 CpG sites that spanned the EDC genomic region. In the discovery cohort, 
screening for possible associations between DNA methylation of CpG sites within the 
EDC and eczema identified five CpG sites that are differentially methylated between 
eczema-affected and eczema-free participants with FDR adjusted p-values < 0.1 (Table 
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5.2). The five identified CpG sites were then tested in women and men participants 
separately. The sex-specific results showed that DNA methylation of the five CpG sites 
was statistically significantly associated with eczema in women but not in men (Table 
5.2). However, the directions of the effect sizes of three out of the five CpG sites 
(cg10959711, cg13493250, and cg01910639) were in agreement between women and 
men. For instance, DNA methylation at cg13493250 locus (located within the LCE1F 
gene promoter region) was, on average, 4% higher in women and by 3% in men, when 
comparing eczema-affect to eczema-free participants. 
 The five identified CpG sites were further tested for association with eczema in 
replication cohort I (Table 5.3). None of the CpG sites showed statistically significant 
association with eczema. The direction of the effect size of two CpG sites (cg10959711 
and cg12048339) was in agreement when comparing results of the discovery cohort 
(Table 5.2) with results of replication cohort I (Table 5.3). The sex-stratified analyses 
showed DNA methylation of two CpG sites in females (cg10959711 and cg12048339) 
and four CpG sites in males (cg10959711, cg13493250, cg03969260, and cg12048339) 
were in agreement, in regard to effect size direction, between the discovery cohort and 
replication cohort I. 
 Finally, associations between the five CpG sites and eczema were tested in the 
replication cohort II (Table 5.4). In regard to statistical significance, none of the 
associations were replicated; however, two CpG sites (cg10959711 and cg12048339) 
showed similar magnitude of association as seen in the discovery cohort. In infant girls, 
DNA methylation of one CpG site (cg12048339) demonstrated similar effect across the 
discovery cohort and replication cohort II. In infant boys, DNA methylation of two CpG 
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sites (cg10959711 and cg01910639) showed similar effects across the discovery cohort 
and replication cohort II. 
 In the analysis that considered both sexes, there were two CpG sites (cg10959711 
and cg12048339) that showed agreement in respect to the magnitude of their effect sizes 
across the three study samples. Furthermore, inspecting the sex-specific analyses showed 
that one CpG site (cg12048339) among female participants and one CpG site among 
male participants (cg10959711) demonstrated similar effect sizes across the three study 
samples. For instance, DNA methylation of cg12048339 was 2% (discovery cohort and 
replication cohort I) and 1% (replication cohort II) lower in eczema-affected as 
compared to eczema-free female participants. On the other hand, DNA methylation of 
cg10959711 locus was 1% (discovery cohort and replication cohort I) and 3% 
(replication cohort II) higher in eczema-affected as compared to eczema-free male 
participants. 
 
5.5 DISCUSSION 
 This explorative study, for the first time, investigated the possible association 
between DNA methylation across the EDC genomic region with eczema in three semi-
independent population based samples. In the discovery cohort, DNA methylation of five 
CpG sites was associated with eczema status. Although results of replicating these 
associations did not demonstrate statistical significance, two CpG sites (cg10959711 and 
cg12048339) showed similar effect sizes across the three study samples. Noticeably, 
DNA methylation of CpG site cg12048339 was associated with eczema specifically 
among female participants of all study cohorts; whereas, DNA methylation of 
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cg10959711 associated with eczema among male participants in all study samples. Such 
results might point towards sex-specific associations between DNA methylation across 
the EDC locus and eczema. Moreover, DNA methylation within the EDC genomic region 
might explain some of the genome-wide linkage and association signals that relate the 
EDC locus with eczema. 
 Both of the identified sex-specific CpG sites are located within genes that belong 
to the S100A gene-family cluster on the EDC locus. The cg12048339 is located within 
the promoter region of S100A6 gene, specifically 1500 base-pairs upstream of 
transcription start site (TSS1500). Similarly, the cg10959711 is located within the 
TSS1500 genomic region of S100A11 gene. The S100A genes, overall, share similar gene 
structure by containing two introns and three exons (exon-2 and exon-3 are translated) 
and encode proteins that, in general, contain two calcium-binding EF-hand motifs [134, 
135]. The S100A proteins are involved in various biological functions and processes, 
such as cell cycle and differentiation, transcription, motility, and inflammation [134]. The 
clustering of S100A genes within the EDC locus, in addition to evidence supporting their 
involvement in epidermal differentiation [135], suggests a biologically-plausible role in 
the pathogenesis of skin-related diseases. For instance, elevated serum levels of S100A8 
and S100A9 proteins have been shown to be related to abnormal differentiation of 
keratinocytes in skin of psoriasis patients [136]. 
 The current state of knowledge suggests that increased methylation  of gene 
promoters is associated with reduced genes expression; whereas, decreased methylation  
is associated with increased gene expression; however, emerging evidence suggest that 
such a regulatory role highly depends on the context in which methylation occurs in the 
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genome and is not limited to methylation of promoter regions [137, 138]. In this study we 
observed that among female participants with eczema as compared to those without 
eczema, DNA methylation of cg12048339 (TSS1500 of S100A11 gene) was reduced, on 
average, by 1% to 2% across the three study samples. In contrast, DNA methylation of 
cg10959711 (TSS1500 of S100A6 gene) among males with eczema as compared to 
eczema-free participants was increased, on average, by 1% to 3% across the study 
cohorts. Such results suggest that altered methylation of CpG sites within the EDC locus 
could serve as markers of eczema in a sex-specific manner.  
 Existing evidence support the regulatory role of DNA methylation on the activity 
of S100A genes [139]. Although we observed associations between DNA methylation in 
two CpG sites with eczema, results of this preliminary report should be interpreted with 
caution. First, DNA methylation, in this report, was not measured in the respective tissue 
of the disease (i.e., skin); therefore, the extent to which DNA methylation measured in 
peripheral blood (or cord blood) relate to other tissues and whether can be used as a 
biomarker for phenotype variation is unclear and an area of current scientific dispute 
[137, 140]. Second, the discrepancy, apart from the two identified CpG sites, in the 
results across the three study samples could be due to (i) the differential phenotype 
expression over age and/or (ii) the dynamic nature of DNA methylation that changes with 
respect to age and environmental exposures. For instance, previously we observed a sex-
reversal in the prevalence of eczema during adolescence period with more girls 
developing eczema and more boys outgrowing their eczema [25], such a sex-switchover 
in the risk could be mediated by changes in DNA methylation. 
 81 
 There is no doubt that this study can only serve as a starting point for future 
studies due to the limited sample sizes of the studied cohorts. The discovery cohorts is the 
largest sample (n = 367) that we studied and from which we obtained the initial 
significant findings. Replications cohorts I and II were smaller in size (n = 146 and n = 
94, respectively) and failed to replicate, in terms of statistical significance, results of the 
discovery cohort. The sex-specific analyses were based on even smaller groups. This 
said, we acknowledge the fact that two out of five CpG sites were in agreement in regard 
to their effect sizes across the three study cohorts. Moreover, the observed modest effect 
sizes are not unusual, apart from cancer studies, for studies investigating complex 
diseases. For example, a 2.07% difference in DNA methylation of the ORMDL3 gene 
when comparing asthmatic (87.90%) to non-asthmatic (85.83%) children has been 
reported [141]. Currently, there is no consensus as to whether modest changes in DNA 
methylation are as important or less important when compared to larger changes in regard 
to the development of complex diseases. To this end, previously we demonstrated that an 
interaction between genetic variants in the FLG gene with adjacent DNA methylation 
predisposed to greater risk of eczema [80]. These results indicated that the association 
between FLG loss-of-function variants and eczema is modulated by DNA methylation. 
Therefore, simultaneously considering the DNA methylation of the EDC locus and the 
underlying genetic variants might provide further insights into the genetics/epigenetics of 
eczema than when considering each factor separately. Taken together, future studies 
should incorporate DNA methylation, genetic predisposition, gene expression, and 
proteins levels to provide a better assessment of the risk. 
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 In conclusion, this exploratory study demonstrated that DNA methylation of the 
EDC genomic region could be an important factor in the development of eczema and 
might as well explain some of the observed genome-wide linkage and association signals 
relating the EDC locus with eczema. Interestingly, we observed gender-specific 
associations between DNA methylation of CpG sites and eczema, which further support 
the fact that eczema development is different across the two sexes. Future studies 
confirming these preliminary observations are needed and should obtain DNA 
methylation profiles from the disease-tissue to increase reliability and relevant of any 
findings. 
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Figure 5.1. Flow diagram of the different analyzed study samples. 
 
IOW birth cohort: 
n = 1,456 
Discovery cohort (F1):  
367 participants (245 girls and 122 
boys), aged 18 years, had DNA 
methylation measurements 
Replication cohort I (F2 parents): 
146 parents (93 women and 53 men) 
had DNA methylation measurements 
- Pregnant women had their DNA 
methylation measured during early (n 
= 66) or late (n = 27) pregnancy 
Females: n = 37 
Males:     n = 5 
New females (n = 9) and 
males (n = 40) participants 
Replication cohort II (F2 Offspring): 
94 newborns (43 girls and 51 boys) 
had their DNA methylation measured 
in cord blood  
Females: n = 47 
Males:     n = 8 
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Table 5.1. Prevalence of eczema in the different study samples stratified by sex 
 Total Females Males p-value
* 
Discovery cohort (F1)     
Eczema at age 18 years, % (n/total) 
12.6 
(46/366) 
15.2 
(37/244) 
7.4 
(9/122) 0.034 
Missing, n 1 1 0  
     
Replication cohort I (F2 parents)     
Eczema, % (n/total) 
15.6 
(22/141) 
21.1 
(19/90) 
5.9 
(3/51) 0.017 
Missing, n 5 3 2  
     
Replication cohort II (F2 offspring)     
Eczema at age 1 year, % (n/total) 
16.7 
(12/72) 
11.8 
(4/34) 
21.1 
(8/38) 0.354 
Missing, n 22 9 13  
* P-value comparing proportions of females to males. 
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Table 5.2. Association of CpG sites in the EDC genomic region with eczema status: results of the discovery cohort 
Both sexes    
Average methylation 
(5
th
 – 95
th
 percentile)    
CpG ID Gene Placement 
Average methylation 
(5
th
 – 95
th
 percentile) Yes eczema No eczema 
Effect size 
(SE)
* 
Raw 
p-value 
FDR adj. 
p-value 
cg10959711 S100A6 TSS1500 0.11 (0.07 – 0.16) 0.12 (0.09 – 0.19) 0.10 (0.07 – 0.16) 0.02 (0.004) 0.00023 0.055 
cg13493250 LCE1F TSS1500 0.38 (0.29 – 0.49) 0.41 (0.31 – 0.52) 0.38 (0.29 – 0.48) 0.03 (0.010) 0.00052 0.055 
cg03969260 SPRR2G 3ʹ UTR 0.93 (0.90 – 0.95) 0.94 (0.92 – 0.95) 0.93 (0.91 – 0.94) 0.01 (0.002) 0.00065 0.055 
cg12048339 S100A11 TSS1500 0.67 (0.62 – 0.72) 0.65 (0.61 – 0.69) 0.67 (0.62 – 0.72) -0.02 (0.005) 0.00118 0.071 
cg01910639 S100A6 Body 0.73 (0.63 – 0.81) 0.75 (0.67 – 0.83) 0.72 (0.62 – 0.80) 0.03 (0.009) 0.00139 0.071 
Female participants        
cg10959711 S100A6 TSS1500 0.11 (0.06 – 0.18) 0.12 (0.09 – 0.22) 0.10 (0.06 – 0.17) 0.02 (0.006) 0.0016  
cg13493250 LCE1F TSS1500 0.38 (0.29 – 0.50) 0.40 (0.31 – 0.52) 0.36 (0.29 – 0.48) 0.04 (0.011) 0.0012  
cg03969260 SPRR2G 3ʹ UTR 0.93 (0.91 – 0.95) 0.93 (0.92 – 0.95) 0.92 (0.91 – 0.95) 0.01 (0.002) 0.0018  
cg12048339 S100A11 TSS1500 0.67 (0.62 – 0.72) 0.65 (0.60 – 0.70) 0.67 (0.62 – 0.72) -0.02 (0.005) 0.0002  
cg01910639 S100A6 Body 0.74 (0.62 – 0.82) 0.75 (0.66 – 0.83) 0.73 (0.61 – 0.72) 0.03 (0.012) 0.0066  
Male participants        
cg10959711 S100A6 TSS1500 0.10 (0.08 – 0.13) 0.11 (0.09 – 0.16) 0.10 (0.08 – 0.13) 0.01 (0.005) 0.0251  
cg13493250 LCE1F TSS1500 0.39 (0.29 – 0.48) 0.42 (0.28 – 0.49) 0.39 (0.29 – 0.48) 0.03 (0.021) 0.1959  
cg03969260 SPRR2G 3ʹ UTR 0.93 (0.91 – 0.94) 0.92 (0.90 – 0.94) 0.93 (0.91 – 0.94) -0.01 (0.003) 0.9959  
cg12048339 S100A11 TSS1500 0.66 (0.62 – 0.71) 0.67 (0.64 – 0.69) 0.66 (0.61 – 0.71) 0.01 (0.011) 0.8144  
cg01910639 S100A6 Body 0.71 (0.65 – 0.75) 0.73 (0.67 – 0.76) 0.71 (0.64 – 0.75) 0.02 (0.012) 0.2849  
SE: Standard error; FDR: False discovery rate; Ajd.: adjusted 
* Effect size is calculated as average methylation difference between eczema-affected and eczema-free participants using linear regression models. Effect sizes of 
the ‘both sexes’ models were adjusted for sex and cell-type composition. 
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Table 5.3. Association of CpG sites in the EDC genomic region with eczema status: results of the replication cohort I 
Both sexes    
Average methylation 
(5
th
 – 95
th
 percentile)   
CpG ID Gene Placement 
Average methylation 
(5
th
 – 95
th
 percentile) Yes eczema No eczema 
Effect size 
(SE)
* 
Raw 
p-value 
cg10959711 S100A6 TSS1500 0.09 (0.08 – 0.11) 0.10 (0.08 – 0.11) 0.09 (0.08 – 0.11) 0.01 (0.003) 0.8798 
cg13493250 LCE1F TSS1500 0.39 (0.29 – 0.51) 0.38 (0.29 -0.51) 0.39 (0.31 – 0.51) -0.01 (0.015) 0.6788 
cg03969260 SPRR2G 3ʹ UTR 0.93 (0.91 – 0.95) 0.92 (0.90 – 0.95) 0.93 (0.91 – 0.95) -0.01 (0.003) 0.2889 
cg12048339 S100A11 TSS1500 0.67 (0.62 – 0.71) 0.65 (0.61 – 0.70) 0.67 (0.62 – 0.71) -0.02 (0.007) 0.2862 
cg01910639 S100A6 Body 0.70 (0.63 – 0.74) 0.69 (0.64 – 0.73) 0.70 (0.63 – 0.74) -0.01 (0.008) 0.5078 
Female participants       
cg10959711 S100A6 TSS1500 0.10 (0.08 – 0.11) 0.10 (0.08 – 0.11) 0.09 (0.08 – 0.11) 0.01 (0.005) 0.7550 
cg13493250 LCE1F TSS1500 0.39 (0.29 – 0.50) 0.37 (0.24 – 0.53) 0.38 (0.29 – 0.50) -0.01 (0.017) 0.4420 
cg03969260 SPRR2G 3ʹ UTR 0.93 (0.91 – 0.95) 0.92 (0.90 – 0.95) 0.93 (0.91 – 0.95) -0.01 (0.004) 0.2898 
cg12048339 S100A11 TSS1500 0.67 (0.61 – 0.70) 0.65 (0.61 – 0.70) 0.67 (0.62 – 0.70) -0.02 (0.007) 0.1428 
cg01910639 S100A6 Body 0.70 (0.65 – 0.74) 0.69 (0.60 – 0.73) 0.70 (0.66 – 0.75) -0.01 (0.008) 0.3577 
Male participants       
cg10959711 S100A6 TSS1500 0.09 (0.08 – 0.11) 0.10 (0.09 – 0.11) 0.09 (0.08 – 0.11) 0.01 (0.006) 0.7200 
cg13493250 LCE1F TSS1500 0.39 (0.31 – 0.51) 0.40 (0.39 – 0.51) 0.39 (0.31 – 0.51) 0.01 (0.037) 0.4226 
cg03969260 SPRR2G 3ʹ UTR 0.93 (0.91 – 0.94) 0.92 (0.91 – 0.93) 0.93 (0.91 – 0.94) -0.01 (0.006) 0.9147 
cg12048339 S100A11 TSS1500 0.67 (0.62 – 0.72) 0.68 (0.64 – 0.71) 0.67 (0.63 – 0.72) 0.01 (0.019) 0.6263 
cg01910639 S100A6 Body 0.68 (0.62 – 0.73) 0.66 (0.65 – 0.72) 0.68 (0.62 – 0.73) -0.02 (0.023) 0.8495 
SE: Standard error; FDR: False discovery rate; Ajd.: adjusted 
* Effect size is calculated as average methylation difference between eczema-affected and eczema-free participants using linear regression models. Effect sizes of 
the ‘both sexes’ models were adjusted for sex and cell-type composition. 
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Table 5.4. Association of CpG sites in the EDC genomic region with eczema status: results of the replication cohort II 
Both sexes    
Average methylation 
(5
th
 – 95
th
 percentile)   
CpG ID Gene Placement 
Average methylation 
(5
th
 – 95
th
 percentile) Yes eczema No eczema 
Effect size 
(SE)
* 
Raw 
p-value 
cg10959711 S100A6 TSS1500 0.19 (0.12 – 0.26) 0.20 (0.09 – 0.33) 0.19 (0.14 – 0.26) 0.01 (0.013) 0.8056 
cg13493250 LCE1F TSS1500 0.38 (0.29 – 0.46) 0.36 (0.25 – 0.45) 0.38 (0.31 – 0.46) -0.02 (0.015) 0.1453 
cg03969260 SPRR2G 3ʹ UTR 0.92 (0.90 – 0.94) 0.91 (0.90 – 0.95) 0.92 (0.89 – 0.94) -0.01 (0.004) 0.9833 
cg12048339 S100A11 TSS1500 0.68 (0.63 – 0.73) 0.68 (0.63 – 0.73) 0.69 (0.64 – 0.73) -0.01 (0.009) 0.3941 
cg01910639 S100A6 Body 0.85 (0.75 – 0.89) 0.82 (0.53 – 0.90) 0.84 (0.77 – 0.89) -0.02 (0.017) 0.6029 
Female participants       
cg10959711 S100A6 TSS1500 0.19 (0.15 – 0.23) 0.17 (0.08 – 0.21) 0.19 (0.15 – 0.23) -0.02 (0.015) 0.1489 
cg13493250 LCE1F TSS1500 0.36 (0.27 – 0.45) 0.32 (0.25 – 0.44) 0.36 (0.28 – 0.43) -0.04 (0.026) 0.1439 
cg03969260 SPRR2G 3ʹ UTR 0.92 (0.89 – 0.94) 0.91 (0.90 – 0.92) 0.92 (0.89 – 0.94) - 0.01 (0.007) 0.3015 
cg12048339 S100A11 TSS1500 0.68 (0.64 – 0.72) 0.67 (0.66 – 0.70) 0.68 (0.64 – 0.72) -0.01 (0.014) 0.7898 
cg01910639 S100A6 Body 0.85 (0.77 – 0.89) 0.83 (0.53 – 0.90) 0.85 (0.80 – 0.89) -0.02 (0.033) 0.5716 
Male participants       
cg10959711 S100A6 TSS1500 0.20 (0.11 – 0.28) 0.24 (0.18 – 0.33) 0.21 (0.11 – 0.28) 0.03 (0.018) 0.1938 
cg13493250 LCE1F TSS1500 0.39 (0.32 – 0.46) 0.39 (0.31 – 0.45) 0.40 (0.32 – 0.48) -0.01 (0.017) 0.5823 
cg03969260 SPRR2G 3ʹ UTR 0.92 (0.90 – 0.94) 0.92 (0.90 – 0.95) 0.91 (0.90 – 0.93) 0.01 (0.006) 0.5499 
cg12048339 S100A11 TSS1500 0.69 (0.63 – 0.74) 0.68 (0.63 – 0.73) 0.70 (0.63 – 0.74) -0.02 (0.013) 0.4397 
cg01910639 S100A6 Body 0.85 (0.75 – 0.89) 0.86 (0.82 – 0.88) 0.84 (0.73 – 0.89) 0.02 (0.016) 0.3421 
SE: Standard error; FDR: False discovery rate; Ajd.: adjusted 
* Effect size is calculated as average methylation difference between eczema-affected and eczema-free participants using linear regression models. Effect sizes of 
the ‘both sexes’ models were adjusted for sex and cell-type composition. 
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CHAPTER 6 
DISCUSSION 
6.1 SECTION STRUCTURE 
In this section I will tie together the major findings of this dissertation and their 
relevant interpretation. In general, results of chapters 3 and 4 will by synthesized together 
as they were (i) based on the same study sample and (ii) investigated the role of FLG 
variants and allergic sensitization on the development of single (chapter 3) and multiple 
(chapter 4) allergic diseases. In contrast, results of chapter 5 will be discussed separately 
since it was based on three semi-independent study samples and investigated the potential 
role of DNA methylation of the EDC genomic locus on the development of eczema. 
 
6.2 OVERVIEW OF FINDINGS 
The first two research-related chapters (i.e., chapters 3 and 4) of this dissertation 
aimed at elucidating the role of FLG variants and allergic sensitization on the 
development of allergic diseases. Chapter 3 focused on the possible effect modification 
by allergic sensitization and/or eczema on the association between “FLG variants and 
asthma” and “FLG variants and rhinitis”. I demonstrated that both allergic sensitization 
and eczema status are possible effect modifiers of the association between FLG variants 
and asthma. In contrast, neither eczema nor allergic sensitization modified the association 
of FLG variants with rhinitis in a statistically significant manner. In chapter 4, I showed 
that the coexistence of eczema, asthma, and rhinitis is prevalent and allergic sensitization
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and FLG variants jointly predisposed to increased risk of allergic comorbidities. On the 
other hand, chapter 5 investigated the role of DNA methylation across the EDC genomic 
region on the risk of eczema. Results of this exploratory study demonstrated possible 
gender-specific associations between DNA methylation of CpG sites and eczema in the 
discovery study sample; however, the results, across the three semi-independent study 
samples, did not identify consistent pattern of associations between DNA methylation of 
CpG sites in EDC locus with eczema 
 
6.3 FLG VARIANTS AND ALLERGIC SENSITIZATION IN RELATION TO ALLERGIC DISEASES 
 Studies investigating the natural history (long-term prognosis) of allergic diseases 
have improved our understanding of the biological mechanisms that underlie the clinical 
manifestation of these complex disorders. For instance, in previous reports we have 
demonstrated that a sex-switchover in the prevalence of eczema [25], asthma [37], and 
rhinitis [33] occurs around puberty, with more adolescent girls being affect. Etiologic 
investigations have indicated the importance of environmental, immunologic, and genetic 
factors in the pathogenesis of allergic diseases [23, 26, 110, 142-144]. Moreover, close 
and complex inter-relatedness between the manifestations of eczema, asthma, and rhinitis 
have been demonstrated [45, 48, 103]; however, common mechanisms and pathways 
underlying their development is an area of ongoing scientific research. The ‘allergic 
march’ concept suggests that allergic disorders develop in a sequential pattern, starting 
with eczema in early infancy and later in childhood developing asthma and rhinitis [41, 
106]. However, supporting replicable evidence and consensus is far from complete [108, 
145, 146]. An opposing concept is the “coexistence” of allergic morbidities [42, 45, 109, 
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115]. Therefore, identifying common risk factors that predispose to the development of 
single and/or multiple allergic diseases is of importance and will further elucidate the 
etiology of such complex diseases. 
 Allergic sensitization (deviated immune responses) has been widely associated 
with different allergic diseases [48, 49, 96]. Similarly, FLG variants (representing 
defective epidermal barrier) have recently emerged as strong independent risk factors for 
eczema [59]. Furthermore, FLG variants increase the risk of asthma and rhinitis only in 
the presence of coexisting eczema [59, 60]. Apart from eczema, it has been suggested 
that FLG variants predispose to allergic disorders of the airways by facilitating the 
penetration of allergens through the defective epidermal barrier, which in turn might lead 
to local and systematic inflammation at distant organs (e.g., lung and nasal tissues) [56, 
147]. In this dissertation I have focused on FLG variants and allergic sensitization as they 
have been considered as common risk factors that predispose and link the manifestation 
of eczema, asthma, and rhinitis [49, 60, 79]. That said, our current state of knowledge 
lacks clear understanding on their single and joint role in the development of single 
(chapter 3) and multiple (chapter 4) allergic diseases. Utilizing the prospective nature of 
the Isle of Wight birth cohort study, I tested if FLG variants interact with allergic 
sensitization and/or eczema on the risk of later asthma and rhinitis. Specifically, I 
investigated as to whether interplay between “FLG variants and allergic sensitization” 
and/or “FLG variants and eczema” predisposed to the development of subsequent asthma 
and rhinitis. Next, I tested whether FLG variants and allergic sensitization jointly 
predisposed to the coexistence of eczema, asthma, and rhinitis. 
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6.3.1 SINGLE ALLERGIC DISEASES 
 Thus far, FLG variants are the strongest and most replicated genetic risk factors 
for eczema development [59, 66]. In a previous report, we have corroborated the reported 
association between FLG variants and eczema and further demonstrated that allergic 
sensitization is an important effect modifier of this association [79]. We showed that FLG 
variants increased the risk of eczema only in the presence of allergic sensitization and the 
combined effect of both risk factors was associated with elevated risk of eczema (RR = 
2.92, 95% CI: 1.47–5.77) that was above and beyond their individual effects [79]. In this 
dissertation, I sought to explore the possibility that allergic sensitization could also 
modify the reported associations of FLG variants with asthma and rhinitis. 
 Prior studies have shown that FLG variants are associated with asthma only in the 
presence of coexisting eczema [59, 66]. However, this possible effect modification by 
eczema was not consistently demonstrated for the association between FLG variants and 
rhinitis [65, 66]. To this end, I have tested the hypothesis that allergic sensitization, rather 
than eczema status, modifies the association of FLG variants with asthma and rhinitis. I 
have tested my hypothesis under two models: (i) concurrent effect models in which both 
the exposure and the outcome coexisted at the same time and (ii) delayed effect models in 
which I used the preceding cumulative allergic sensitization status (or eczema status), i.e. 
all SPTs results (or eczema status) from assessments that are prior to the outcome 
assessment, when testing the interaction between FLG variants and allergic sensitization 
(or eczema) on the risk of subsequent asthma/rhinitis. 
In stratified analyses (concurrent model), both eczema and allergic sensitization 
status modulated the association between FLG variants and asthma. Statistical 
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interactions on multiplicative scale were tested to determine whether the observed 
heterogonous effects were statistically significantly different. A statistically significant 
interaction was found only between FLG variants and allergic sensitization on the risk of 
asthma. In delayed effect models, which take the time order of risk factors and disease 
occurrences into account, I have tested the interaction of ‘FLG variants with preceding 
allergic sensitization’ and ‘FLG variants with preceding eczema’ on the risk of 
subsequent asthma. Results of delayed effect models showed that FLG variants in 
interaction with preceding allergic sensitization and preceding eczema increased the risk 
of subsequent asthma. Hence, indicating that both allergic sensitization and eczema might 
act as effect modifiers for the association between FLG variants and asthma. 
In regard to rhinitis, results of stratified analyses (concurrent model) demonstrated 
that eczema status did not modify the association between FLG variants and rhinitis; 
however, this association was modified when stratifying by allergic sensitization status. 
But, there was no evidence for an interactive effect (statistical interaction) neither 
between FLG variants and eczema nor between FLG variants and allergic sensitization on 
the risk for rhinitis. Similarly, results of delayed effect models showed that neither 
preceding eczema nor preceding allergic sensitization interacted with FLG variants on the 
risk of subsequent rhinitis. 
These findings indicate that FLG variants may need eczema and/or allergic 
sensitization to execute their adverse effects on asthma. The finding of an interaction 
between FLG variants and allergic sensitization in this study improves our understanding 
of the possible link between genetics of the epidermal barrier (i.e., FLG variants) and a 
respiratory disorder (i.e., asthma). Such an observation further supports the hypothesis 
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that cutaneous sensitization priming, partially facilitated by FLG variants, could lead to 
local and systematic inflammation at distant organs (e.g., lung) [56, 98]. Our results of an 
interactive effect between FLG variants and allergic sensitization on the risk of asthma 
and the lack of such interaction on the risk of rhinitis suggest that the pathway through 
which FLG variants predispose to asthma and rhinitis may be different. For instance, the 
expression of filaggrin protein was not detected in the human bronchial epithelium; 
however, it has been shown that filaggrin is expressed in the nasal vestibule [64, 94]. 
That said, the extent to which filaggrin expression in the nasal vestibular lining influence 
the development of rhinitis is yet to be investigated by future studies. 
 In summary, the first part of this dissertation has demonstrated that (i) FLG 
variants are associated with single allergic diseases such as asthma and rhinitis and (ii) 
allergic sensitization and eczema status act as possible effect modifiers of the association 
between FLG variants and asthma. The combined effects of ‘preceding allergic 
sensitization and FLG variants’ and ‘preceding eczema and FLG variants’ increased the 
risk of subsequent asthma by 4.93-fold and 3.33-fold, respectively, during the study 
period (i.e., the first 18 years of life). In contrast, the association between FLG variants 
and rhinitis was not modulated by either allergic sensitization or eczema status. Taken 
together, our results demonstrated differential etiological pathways underlying the 
development of asthma and rhinitis and future studies corroborating our observations are 
needed. 
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6.3.2 MULTIPLE ALLERGIC DISEASES 
 After exploring the role of allergic sensitization and FLG variants on the 
development of single allergic diseases, I investigated their single and joint contribution 
towards the development of allergic comorbidities (i.e., coexistence of eczema, asthma, 
and rhinitis). First, I constructed eight non-overlapping combinations of the three allergic 
disorders (Table 2.1), which were used in subsequent analyses for this part of the 
dissertation.  
 Although previous studies have demonstrated the importance of allergic 
sensitization and FLG variants on the development of single allergic diseases [49, 60, 
96], no prior study have investigated the joint role of both risk factors on the development 
of allergic comorbidities. In this dissertation, I have demonstrated that the coexistence of 
“eczema, asthma, and rhinitis” affect around 2% of the study population. Both risk 
factors, when tested separately, were associated with single and multiple allergic 
diseases. However, FLG variants, when adjusting for the effect of allergic sensitization, 
did not show any association with allergic disorders. Remarkably, interactions between 
the two risk factors were associated with substantial combined effects on the risk of 
allergic comorbidities. For instance, a 23-fold increased risk for having “eczema, asthma, 
and rhinitis” was associated with the presence of both FLG variants and allergic 
sensitization. Moreover, we estimated that approximately 21% to 49% of allergic 
comorbidities in the population may be attributed to the presence of both FLG variants 
and allergic sensitization. 
 In summary, results of this part of the dissertation suggests that comorbidities of 
eczema, asthma, and rhinitis are prevalent and both allergic sensitization and FLG 
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variants are common risk factors that predispose to the comorbidity of allergic disorders. 
The combination of both risk factors was associated with elevated risk of coexisting 
allergic manifestations. Although in the previous section of this dissertation I showed that 
FLG variants and allergic sensitization predispose to single allergic diseases, in this 
section I further demonstrated the importance of their joint role on the co-manifestation 
of allergic diseases. Therefore, simultaneously considering the contribution of genetic 
predisposition toward a defective skin barrier (i.e., FLG variants) and the propensity for 
immune dysregulation (i.e., allergic sensitization) provided new and improved insights 
into the pathogenesis of allergic disorders. 
 
6.3.3 STRENGTHS AND LIMITATIONS 
 The first two research-related chapters (i.e., chapters 3 and 4) in this dissertation 
were based on information collected in the Isle of Wight birth cohort study. Major 
strengths of our prospective study, covering the first 18 years of life, are the repeated 
phenotyping, objective assessments of allergic sensitization status, and the low loss to 
follow-up (ranged from 5% to 17%). Moreover, the majority (80%) of the study 
participants were genotyped for FLG variants common among populations of European 
ancestry. We showed, previously, that the genotyped study participants did not differ 
from the total cohort with regard to multiple characteristics [79]. Hence, there is no 
indication of selection bias that could pose a threat to the validity of our study. 
Misclassification of eczema cases is minimal since a high proportion of subjects showed 
typical manifestation of eczema in the usual locations (antecubital or popliteal fossae, 
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ankles, face or neck for 97% at 1 year, 91% at 2 years, 75% at 4 years, 86% at 10 years 
and 76% at 18 years) [25].  
 Potential limitations are the definition of asthma and rhinitis symptoms in early 
life. Our asthma conclusion at ages 10 and 18 years followed the ISAAC criteria [4], 
which was at that time not available for assessments at age 1, 2, and 4 years. Although 
slightly different methods were used to define asthma, in a previous report we have 
shown that the minor change in asthma definition over time did not influence the validity 
of our asthma classification (i.e, no noticeable change in asthma prevalence up to 10 
years of age) [37]. In addition, since it is difficult to differentiate between infectious and 
other forms of rhinitis in infancy, the elevated prevalence at 1-or-2 years might have been 
influenced by misclassifying ‘viral induced infectious rhinitis’ [33]. However, by 
applying repeated measurements analysis based solely on assessments later in childhood 
and adolescence (4, 10, and 18 years), we believe that the influence of the possible 
misclassification of rhinitis at 1-or-2 years on the overall results of the study is minimal, 
since similar results were obtained. Moreover, since SPTs at age 1-or-2 years were 
performed on symptomatic children, we speculate that selection bias leading to 
underestimated RRs might have been induced. Although proportions of SPT positivity at 
ages 1-or-2 years (20.6%) and 4 years (19.6%; SPT performed irrespective of symptoms) 
were similar, RRs associating allergic sensitization at age 1-or-2 years with outcomes 
(i.e., eczema, asthma, and rhinitis) at the same age tended to be smaller than RRs relating 
allergic sensitization at age 4 years with outcomes at the same age, since also the 
reference group had some symptoms. Hence, the estimated RRs at age 1-or-2 might be 
underestimated; however, the extent of the possible selection bias is minimal since our 
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results did not noticeably change when we excluded the 1-or-2 years follow-up data from 
the analyses. Such observations further demonstrate the robustness of the GEE method in 
providing population averaged estimates (RRs) while accounting for the within-subject 
correlations of repeated measurements. 
 
6.4 DNA METHYLATION OF THE EDC AND ECZEMA RISK 
 The third research-related chapter (i.e., chapter 5) of this dissertation focused on 
the role of DNA methylation across the EDC genomic region in relation to eczema status. 
In this explorative study, I have screened for associations between DNA methylation of 
256 CpG sites across the EDC locus with eczema status at age 18 years (discovery 
cohort), and subsequently replicated the significant findings in two semi-independent 
cohorts. Results of this analysis showed that DNA methylation of two CpG sites 
(cg10959711 and cg12048339) demonstrated similar effect sizes across the three study 
samples. Noticeably, DNA methylation of CpG site cg12048339 was associated with 
eczema specifically among female participants of all study cohorts; whereas, DNA 
methylation of cg10959711 associated with eczema among male participants in all study 
samples. Such results might point towards sex-specific associations between DNA 
methylation across the EDC locus and eczema. 
 Both of the identified sex-specific CpG sites are located within genes that belong 
to the S100A gene-family cluster on the EDC locus. The cg12048339 is located within 
the promoter region of S100A6 gene, specifically 1500 base-pairs upstream of 
transcription start site (TSS1500). Similarly, the cg10959711 is located within the 
TSS1500 genomic region of S100A11 gene. The S100A genes, overall, share similar gene 
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structure by containing two introns and three exons (exon-2 and exon-3 are translated) 
and encode proteins that, in general, contain two calcium-binding EF-hand motifs [134, 
135]. The S100A proteins are involved in various biological functions and processes, 
such as cell cycle and differentiation, transcription, motility, and inflammation [134]. The 
clustering of S100A genes within the EDC locus, in addition to evidence supporting their 
involvement in epidermal differentiation [135], suggests a biologically-plausible role in 
the pathogenesis of skin-related diseases. In this study we observed that among female 
participants with eczema as compared to those without eczema, DNA methylation of 
cg12048339 (TSS1500 of S100A11 gene) was reduced, on average, by 1% to 2% across 
the three study samples. In contrast, DNA methylation of cg10959711 (TSS1500 of 
S100A6 gene) among males with eczema as compared to eczema-free participants was 
increased, on average, by 1% to 3% across the study cohorts. Such results suggest that 
altered methylation of CpG sites within the EDC locus could serve as markers of eczema 
in a sex-specific manner. 
 
6.4.1 STRENGTHS AND LIMITATIONS 
 There is no doubt that this study can only serve as a starting point for future 
studies due to the limited sample sizes of the studied cohorts. The discovery cohorts is the 
largest sample (n = 367) that we studied and from which we obtained the initial 
significant findings. Replications cohorts I and II were smaller in size (n = 146 and n = 
94, respectively) and failed to replicate, in terms of statistical significance, results of the 
discovery cohort. The sex-specific analyses were based on even smaller groups. 
Moreover, DNA methylation, in this report, was not measured in the respective tissue of 
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the disease (i.e., skin); therefore, the extent to which DNA methylation measured in 
peripheral blood (or cord blood) relate to other tissues and whether can be used as a 
biomarker for phenotype variation is unclear and an area of current scientific dispute 
[137, 140]. The discrepancy, apart from the two identified CpG sites, in the results across 
the three study samples could be due to (i) the differential phenotype expression over age 
and/or (ii) the dynamic nature of DNA methylation that changes with respect to age and 
environmental exposures. For instance, previously we observed a sex-reversal in the 
prevalence of eczema during adolescence period with more girls developing eczema and 
more boys outgrowing their eczema [25], such a sex-switchover in the risk could be 
mediated by changes in DNA methylation. 
 
6.5 CONCLUSION 
 In this dissertation I have investigated the role of FLG variants (representing an 
impaired epidermal barrier) and allergic sensitizations (representing deviated immune 
responses) on the development of single and multiple allergic diseases. Results of this 
dissertation clearly demonstrated that FLG variants and allergic sensitization are common 
factors that predispose and link the manifestation of different allergic diseases (i.e., 
eczema, asthma, and rhinitis). First, I have shown that allergic sensitization and eczema 
modulated the association between FLG variants and asthma, but not rhinitis. Hence, 
implying that the mechanisms and pathways through which FLG variants predispose to 
increased risk of asthma and rhinitis may be different. Second, a coexistence of allergic 
disorders was demonstrated to be frequent; and allergic sensitization and FLG variants 
jointly increased risk of allergic comorbidities. The coexistence of allergic diseases may 
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represent more severe and complex clinical phenotypes that require more and longer 
medical care. The interactive effect and the elevated proportion of allergic comorbidities 
associated with allergic sensitization and FLG variants emphasize their joint importance 
in the pathogenesis of allergic disorders. Third, DNA methylation across the EDC 
genomic region might influence the risk of eczema in a sex-specific manner.  
 In summary, this dissertation provided insights on (i) the joint role of FLG 
variants and allergic sensitization on the development of single and multiple allergic 
diseases and (ii) the role of DNA methylation of the EDC locus on the development of 
eczema. Therefore, results of this dissertation helped improve our ability to better identify 
and stratify those who share similar risk characteristics, which may also enhance clinical 
management and the development of efficient intervention and prevention strategies. 
Future studies corroborating our findings of the joint role of FLG variants and allergic 
sensitization on the development of single and multiple allergic diseases are needed. 
Moreover, future studies confirming our preliminary observations of sex-specific 
associations between DNA methylation and eczema are needed and should obtain DNA 
methylation profiles from the disease-tissue (i.e., skin) to increase reliability and enhance 
relevance of any findings. 
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